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Abstract 
Adaptive interventions (AIs) are increasingly becoming popular in behavioral sciences. An 
AI is a sequence of decision rules that specify for whom and under what conditions different 
intervention options should be offered, in order to address the changing needs of individuals as 
they progress over time. The sequential, multiple assignment, randomized trial (SMART) is a 
novel trial design that was developed to aid in empirically constructing effective AIs. The 
sequential randomizations in a SMART often yield multiple AIs that are embedded in the trial by 
design. Many SMARTs are motivated by scientific questions pertaining to the comparison of such 
embedded AIs. Existing data analytic methods and sample size planning resources for SMARTs 
are suitable only for superiority testing, namely for testing whether one embedded AI yields better 
primary outcomes on average than another. This calls for non-inferiority/equivalence testing 
methods, since AIs are often motivated by the need to deliver support/care in a less costly or less 
burdensome manner, while still yielding benefits that are equivalent or non-inferior to those 
produced by a more costly/burdensome standard of care. Here, we develop data analytic methods 
and sample size formulas for SMART studies aiming to test the non-inferiority or equivalence of 
one AI over another. Sample size and power considerations are discussed with supporting 
simulations, and online sample size planning resources are provided. A simulated data analysis 
shows how to test a non-inferiority or equivalence hypothesis with SMART data. For illustration, 
we use an example from a SMART study aiming to develop an AI for promoting weight loss 
among overweight/obese adults. 
 
Keywords: Adaptive interventions, sequential, multiple assignment, randomized trial (SMART), 
non-inferiority, equivalence, power 
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Introduction 
 High heterogeneity in response to behavioral interventions motivates the development of 
adaptive interventions (Collins, Murphy, & Bierman, 2004). In adaptive interventions (AIs), 
different intervention options (e.g., different types, intensities or modalities of delivery of 
treatment) are offered based on ongoing information about the individual’s changing conditions. 
An AI is not an experimental design; it is an intervention design (i.e., the approach and specifics 
of an intervention program; see Nahum-Shani et al., 2017) that seeks to address the unique and 
changing needs of individuals as they progress over time through an intervention program. An AI 
(also known as a dynamic treatment regime in the statistical literature; see, e.g., Murphy, 2003; 
Chakraborty & Moodie, 2013; Kosorok & Moodie, 2016) is a protocol that guides for whom and 
under what conditions different intervention options should be offered, typically operationalized 
using a sequence of decision rules involving some tailoring variables. AIs have been discussed, 
investigated, and applied across various domains of psychological sciences, including health 
psychology (e.g., Nahum-Shani et al., 2015; Thomas & Bond, 2015), clinical psychology (e.g., 
Connell, Dishion, Yasui, & Kavanagh, 2007; Pelham et al., 2016), educational psychology (e.g., 
Schaughency & Ervin, 2006; Walkington, 2013), and organizational psychology (Howard & 
Jacobs, 2016; Eden, 2017).   
The development of an AI should be guided by evidence (empirical, theoretical and/or 
practical). However, in many cases existing evidence is insufficient to inform the development of 
effective AIs; scientific questions might arise concerning which intervention option to offer, for 
whom, and under what conditions. The sequential, multiple assignment, randomized trial 
(SMART; Lavori & Dawson, 2000, 2004; Thall, Millikan, & Sung, 2000; Murphy, 2005) is a novel 
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experimental design that was developed to aid in the construction of empirically grounded AIs. In 
a SMART, some or all participants are randomized more than once, with the sequential 
randomizations typically resulting in several AIs that are embedded in the SMART by design. 
Many SMARTs are motivated by scientific questions concerning the comparison of these 
embedded AIs.  
       As the importance of developing evidence-based AI is increasingly acknowledged in 
many areas of behavioral and psychological research, SMART designs are experiencing rapid 
uptake despite being relatively new. For example, in the area of clinical psychology, SMARTs 
were employed to develop AIs for promoting weight loss among African American adolescents 
(Naar-King et al., 2016), to develop dynamic strategies for re-engaging individuals in treatment 
(McKay et al., 2015), to optimize the use of contingency management in the treatment of substance 
use (NIH/NIAAA R01AA021446; PI: Petry; Petry et al., 2018), and to develop an adaptive 
behavioral smoking cessation intervention for people living with HIV (NIH/NIMH 
R01DA034537; PI: Ledgerwood). In the area of health psychology, SMARTs have been 
recommended as an experimental tool that can be used to inform the development of adaptive 
behavior change interventions that capitalize on advances in mobile and wireless technology 
(Riley et al., 2015). In organizational psychology, Howard and Jacobs (2016) employed a SMART 
to optimize the sequencing of training methods, Eden (2017) discussed the utility of the SMART 
as an experimental approach that can inform the adaptation of organizational policies and 
practices. In their introduction to AIs and SMARTs in the area of educational and school 
psychology, August, Piehler and Miller (2018) provide multiple examples of SMART applications 
in this area. Many other examples of psychological research involving or highlighting the scientific 
utility of the SMART exist in the extant literature (see e.g., Lei et al., 2012; Lu et al., 2016).  
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Similarly, new methodologies have been developed to enable investigators to analyze data 
arising from SMART studies (Nahum-Shani et al., 2012a; Chakraborty, Laber, & Zhao, 2013; 
Chakraborty, Ghosh, Moodie, & Rush, 2016; Laber, Lizotte, Qian, Pelham, & Murphy, 2014; 
Shortreed, Laber, Stroup, Pineau, & Murphy, 2014; Zhao, Zeng, Laber, & Kosorok, 2015a; 
Ertefaie, Shortreed, & Chakraborty, 2016) and to plan sample size for SMARTs (Oetting et al., 
2011; Kidwell & Wahed, 2013; Laber et al., 2016). Several tutorial manuscripts have provided 
guidelines specific to psychological and behavioral scientists considering this experimental 
approach (see Almirall et al., 2014; Nahum-Shani et al., 2012a; Nahum-Shani et al., 2012b; and 
Lei et al., 2012). These tutorials review various types of SMART designs, offer an accessible 
introduction to data analytic methods that can be used with data arising from a SMART, and review 
sample size considerations. However, an important gap exists with respect to these methodologies.  
Existing methodologies for analyzing data, and for planning sample size for SMART 
studies  are suitable only for superiority testing, namely for testing whether one embedded AI 
yields better primary outcome on average than another. However, the development of AIs often 
requires addressing scientific questions concerning non-inferiority or equivalence. Specifically, 
many AIs are motivated by the need to deliver support/care in a less costly or less burdensome 
manner (Lei et al., 2012; Nahum-Shani et al., 2017), while still yielding benefits that are equivalent 
or non-inferior to those produced by more costly or burdensome interventions that represent the 
standard of care. While Chuang-Stein, Follman, and Chappell (2014) commented about the 
potential role of non-inferiority testing in the context of a SMART design, to the best of our 
knowledge, there has been no follow up work on this topic in terms of developing the actual tests 
and associated sample size resources. This represents a gap in the science of AIs, given that the 
motivation to minimize burden and cost compared to established behavioral intervention 
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approaches underlie the development of AIs in various health (Collins, Murphy, & Strecher, 2007; 
Riley, Rivera, Atienza, Nilsen, Allison, & Mermelstein, 2011), academic (Almirall et al., 2018a), 
and clinical (Page et al., 2016; Pelham et al., 2016) domains. The goal of this manuscript is to 
expand the methodological toolbox available to psychological and behavioral researchers 
considering a SMART by developing data analytic methods and sample size formulas for SMART 
studies that are motivated by primary scientific questions concerning the non-inferiority or 
equivalence of one AI over another.  
We begin by providing a brief review of AIs and SMART studies followed by other types 
of SMART designs and commonly used data analysis methods with software tools. After 
developing the general setup and introducing notation, we discuss data analytic methods and 
related sample size planning resources for SMARTs that are motivated by non-inferiority testing, 
and then for SMARTs that are motivated by equivalence testing. Finally, we present simulation 
studies to validate the proposed methodologies. We also develop an online tool that implements 
our methodology. Technical details, as well as an illustration of data analysis using simulated data 
are provided in the Appendix. Throughout, for illustration, we use an example from the SMART 
Weight Loss Management study (ClinicalTrials.gov Identifier: NCT02997943), which aims to 
develop an AI that integrates mobile technology into the treatment of overweight/obese adults.   
Adaptive Interventions (AI)  
       An AI is a sequence of individualized treatments that use ongoing information about the 
individual’s progress (e.g., early signs of non-response or non-adherence) to decide whether and 
how the intervention should be modified. An AI consists of four main elements: (a) decision points, 
namely points in time in which a decision should be made concerning whether and how to 
intervene; (b) intervention options, which are different types, dosages/intensities or delivery 
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modalities that may be used/offered at any given decision point; (c) tailoring variables, namely 
baseline and time-varying information about the individual that is useful in deciding the 
type/dose/modality of the intervention at each decision point; and (d) decision rules, which link 
the tailoring variables to intervention options, specifying which intervention option to offer, for 
whom, and under what conditions; there is a decision rule for each decision point (Almirall et al., 
2014; Nahum-Shani et al., 2012a). An AI is a multi-stage process, where each stage corresponds 
to a period of time following a decision point in which the individual experiences the assigned 
intervention option; the assigned intervention option in at least one of the stages is tailored based 
ongoing (time-varying) information about the participant, namely information that may change 
over time as a result of prior intervention stages (e.g., response to prior intervention, level of 
adherence to initial treatment, or motivational changes during the previous stage) (Nahum-Shani 
et al., 2017).   
As an example, consider an AI for promoting weight loss among overweight/obese adults 
(Figure 1). At the first stage of this AI, a mobile app is offered to all individuals; this app is 
designed to support self-monitoring of dietary intake and physical activity. The individual’s 
response status is determined at weeks 2, 4, and 8 based on the amount of weight loss. As long as 
the individual is losing at least 0.5 lb. on average per week, s/he is classified as a responder; 
otherwise the individual is classified as a non-responder. As soon as the individual is classified as 
a non-responder, s/he transitions to the second stage of this AI, wherein additional support is 
offered in the form of weekly coaching sessions. As long as the individual is responsive, s/he 
continues with mobile app alone. This intervention is adaptive because it uses ongoing information 
about the individual’s response status to decide whether or not coaching should be added to the 
mobile weight loss app. The following decision rule specifies the weight loss AI: 
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At program entry, 
 First-stage intervention option=mobile app  
Then, at weeks 2, 4, and 8 
 If response status = non-responder  
    Then, second-stage intervention option=add coaching (and stop assessing response status)  
 Else, continue with app alone (and continue assessing response status until week 8).       
   
     In this AI, there are decision points at program entry and at weeks 2, 4, and 8. The 
intervention options include a mobile app (offered to all participants at the first stage), and two 
subsequent tactics: add coaching and continue with app alone (employed at the second stage 
depending on the participant’s response status). The tailoring variable in this AI is the participant’s 
response status. The decision rule specifies how information about the individual’s response status 
at weeks 2, 4, and 8 should be used to tailor the second-stage intervention options, namely to decide 
who should receive more support in the form of coaching and who should continue with app alone.  
The weight loss AI described above is motivated by considerations pertaining to cost and 
burden. Coaching is an effective, yet relatively costly and burdensome weight loss treatment 
component (The Diabetes Prevention Program Research Group, 2003; Appel et al., 2011). The 
mobile app is less costly and less burdensome. However, empirical evidence suggests that not all 
individuals benefit sufficiently from using a mobile app to lose weight; about 50% are unlikely to 
achieve ultimate treatment goals. Importantly, empirical evidence suggests that these individuals 
can be identified early, based on insufficient weight loss during the first few weeks of mobile app 
usage (Spring, Pellegrini, & Nahum-Shani, 2014). Hence, instead of offering coaching to all 
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individuals, this AI starts with the less costly/burdensome treatment component (mobile app) and 
then adds coaching only to those participants who need it most, namely those who show early signs 
of non-response. As long as the individual is responsive, s/he continues with the less 
costly/burdensome treatment component. This AI represents a more cost-effective approach than 
offering coaching sessions to all individuals throughout the intervention program. 
     More generally, AIs are typically motivated by evidence indicating that the same 
intervention approach is not beneficial to all individuals in the target population, and that it is 
possible to identify early those individuals who are unlikely to benefit ultimately. AIs are designed 
to modify the intervention (e.g., increase the intensity of current intervention, switch to another 
intervention, or augment with another type of intervention) when an individual shows early signs 
of non-response, in order to prevent ultimate non-response and maximize the number of 
individuals who benefit from the intervention program. The scientific motivation for AIs and the 
advantages of this approach over a fixed, one-size-fits-all intervention approach have been 
extensively discussed in the extant literature (see Collins, Murphy, & Bierman, 2004; Nahum-
Shani et al., 2012a; Almirall et al., 2014). Practically, AIs are intended to guide the efforts by 
therapists, clinicians, teachers and organizations to provide tailored treatments, practices and 
programs to individuals in order to address their unique and changing needs. The protocolized (i.e., 
pre-specified) nature of AIs increases their replicability in a real-world implementation, as well as 
in research aiming to optimize and evaluate their effectiveness.   
The sequential, multiple assignment, randomized trial (SMART) 
     The SMART is an experimental trial design that involves multiple stages of randomizations; 
each stage corresponds to scientific questions concerning the selection and individualization of 
intervention options at particular decision points in an AI. As an example, consider the SMART 
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weight loss management study for integrating mobile technology in the treatment of 
obese/overweight adults (R01 DK108678; see Figure 2). At program entry, all individuals are 
randomized with equal probability (0.5) to one of two first-stage intervention options, either (1) 
mobile app alone (App) or (2) a mobile app combined with weekly coaching sessions 
(App+Coaching). Response status is assessed at weeks 2, 4, and 8. As soon as the individual is 
classified as a non-responder s/he is re-randomized with equal probability (0.5) to one of two 
second-stage augmentation tactics: either (1) modest augmentation, which consists of adding 
another technology-based intervention component in the form of supportive text messages, or (2) 
vigorous augmentation, which consists of adding supportive text messages combined with a more 
traditional weight loss intervention component (either coaching or meal replacement) that the 
individual was not offered initially. As long as the individual is classified as responsive, s/he 
continues with the initial intervention option and is not re-randomized.  
     The sequential randomizations in the SMART weight loss study are restricted: only non-
responders are re-randomized to second stage intervention options, whereas responders are not re-
randomized. This restriction is consistent with the scientific questions motivating the weight loss 
SMART. Specifically, this study was designed to address open scientific questions concerning the 
selection of front-line treatments and the selection of augmentation tactics for non-responders. For 
responders, sufficient evidence exists to inform the selection of subsequent tactics. As long as the 
individual is responsive, the likelihood of achieving ultimate weight loss goals is high and hence 
continuing with the initial intervention option is both logical (if it’s not broken, don’t fix it) and 
resource efficient (Spring et al., 2017; Waring et al., 2014). Because different subsequent 
intervention options are considered for responders (continue) and non-responders (modest vs. 
vigorous augmentation), response status is embedded as a tailoring variable in this SMART by 
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design. Such multi-stage restricted randomizations give rise to several AIs that are embedded in 
the SMART. Table 1 presents the four AIs that are embedded in the SMART weight loss study 
and the corresponding experimental subgroups that are consistent with each. Notice that a 
simplified version of one of these AIs was described earlier (in Figure 1). Specifically, embedded 
in the SMART weight loss study is an AI (AI #1) which, similar to the AI described in Figure 1, 
recommends initiating treatment with App alone, and then to augment with coaching (and 
supportive text messaging) as soon as the individual exhibits early signs of non-response, and 
continue with app alone as long as the individual is responding. Participants in subgroups A and 
C in Figure 2 are consistent with this embedded AI.    
     An important scientific question motivating the SMART weight loss study concerns the 
comparison of AI #1, which recommends coaching only to individuals who show early signs of 
non-response; and AI #3, which recommends coaching to all individuals in terms of long-term 
(month 6) weight loss. Specifically, AI #3 recommends to initiate treatment with App and 
coaching, and then to vigorously augment with supportive text messaging and meal replacement 
as soon as the individual exhibits early signs of non-response, and to continue with App and 
coaching as long as the individual is responsive. Participants in subgroups D and F in Figure 2 are 
consistent with this embedded AI. The rationale for this comparison relates to cost and burden. 
Because AI #3 recommends coaching throughout, it is likely to be effective, yet relatively costly 
and burdensome. AI #1, on the other hand, offers coaching only to those individuals who seem to 
need it most (i.e., early non-responders), hence it is hypothesized to be non-inferior, namely no 
less effective than AI #3. If AI #1 is equally or more beneficial in terms of ultimate weight loss 
compared to AI #3, then the former should be selected for real-world implementation because it is 
less costly and/or burdensome.   
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Other Types of SMART Designs 
As noted earlier, given the scientific questions motivating the SMART weight loss study, 
the sequential randomizations in this SMART are restricted such that only non-responders are re-
randomized to second-stage intervention options, whereas responders continue with their assigned 
initial intervention option. Although this type of design is highly common (Almirall et al., 2018b),  
other forms of SMARTs exist, depending on the scientific questions motivating the study. These 
include (a) SMARTs in which the second-stage randomization is not restricted, such that all 
participants are re-randomized to second-stage intervention options regardless of their early 
response status (see the remaking recess SMART in Figure 5 of Almirall et al., 2018b); (b) 
SMARTs in which the second-stage randomization is restricted such that only non-responders to 
a specific first-stage intervention option (e.g., App alone) are re-randomized to second-stage 
options, whereas non-responders to the alternative first-stage intervention option (e.g., App + 
Coaching) as well as all responding participants are offered pre-specified second-stage 
interventions (see the SMART study for developing an AI for minimally verbal children with 
autism spectrum disorder in Figure 1 of Almirall et al., 2016); and (c) a SMARTs in which the 
second-stage randomization is restricted such that different second-stage intervention options are 
considered for responders vs. non-responders (e.g., responders are re-randomized to two types of 
maintenance interventions and non-responders are re-randomized to two types of rescue 
interventions; see the Extending Treatment Effectiveness of Naltrexone SMART study in Figure 
1 of Nahum-Shani et al., 2017). 
The extant literature on SMARTs offers additional examples and details concerning different types 
of SMARTs that vary in terms of the re-randomization scheme (see Almirall et al., 2018b; Kidwell, 
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2016; Lei et al., 2012; Nahum-Shani et al., 2012a) the number of randomization stages (i.e., 
considering more than two stages of randomization; see Chakraborty et al., 2016), and the level 
(individual vs. cluster) at which randomizations occur (see NeCamp, Kilbourne, & Almirall, 2017 
for a discussion of cluster-randomized SMARTs). For simplicity of illustration, the current 
manuscript focuses solely on the type of SMART employed in the weight loss study discussed 
above (Figure 2), namely a SMART that employs two stages of randomization, where all 
individuals are randomized initially to two first-stage intervention options and only non-
responding individuals are re-randomized subsequently to two second-stage intervention options. 
Given that this type of SMART has become one of the most popular forms of SMARTs, it is often 
considered the ‘prototypical SMART’ (see Almirall et al., 2018b; Nahum-Shani & Dziak, 2018; 
NeCamp et al., 2017).  
 
Data Analysis Methods and Software Tools 
Data obtained from SMART designs require advanced data analytic methods to analyze them. To 
compare two adaptive interventions embedded within a SMART, Oetting et al. (2011) and Nahum-
Shani et al. (2012a) proposed a z-statistic based approach and an inverse probability weighting 
approach respectively. In recent years, Q-learning, a stage-by-stage recursive estimation procedure 
(Murphy, 2005; Nahum-Shani et al., 2012b, Chakraborty, Laber & Zhao, 2013) and its variations 
like interactive Q-learning (Laber, Linn & Stefanski, 2014) have been frequently used to estimate 
optimal AIs from SMART data. Other noteworthy methods to estimate an optimal AI include 
classification-based outcome-weighted learning (Zhao et al., 2012, 2015a) and value-search 
methods based on (augmented) inverse probability weighted estimators (Zhang et al., 2012a, 
2012b). Quite a few software packages are available to analyze data according to the various 
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available methods. For example, both the R-package ‘qLearn’ and the SAS procedure ‘PROC 
QLEARN’ can be used to estimate optimal AIs using Q-learning and construct associated 
bootstrap-based confidence intervals, based on two-stage SMART data. More recent R-packages 
like ‘DTRlearn’ and ‘DynTxRegime’ implement some of the other methods mentioned above, in 
addition to Q-Learning, that all aim to estimate the optimal AI.  
 
Non-Inferiority and Equivalence Testing  
Existing methods for using SMART study data to compare AIs (e.g., Nahum-Shani et al., 
2012a) and associated power planning resources (Oetting et al., 2011; Kidwell & Wahed., 2013), 
are suitable for traditional superiority testing, where the goal is to investigate whether one AI is 
more efficacious than another. However, in non-inferiority testing, the goal is to establish that a 
new intervention yields favorable outcomes that, when compared to another active control 
intervention (i.e., an intervention approach with established evidence of effectiveness), are not 
below some pre-stated non-inferiority margin (Seaman & Serlin, 1998; Piaggio et al., 2006; 
Wellek, 2010). The non-inferiority margin captures how close the new intervention must be to the 
other in terms of the expected outcome in order for the new intervention to be considered non-
inferior to the other. Practically, the margin is the maximum clinically acceptable difference in 
favor of the active control intervention that one is willing to accept in return for the secondary 
benefits (e.g., lower cost, burden and /or side effects) of the new intervention. In the SMART 
weight loss study, the goal is to test the non-inferiority of AI #1 with respect to AI #3. AI #3 
represents an active control as it offers coaching (a treatment component with established evidence 
of effectiveness) throughout but at the expense of added cost and burden, whereas AI #1 represents 
a novel approach that initiates treatment with a less costly/burdensome treatment component (a 
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mobile app) and then recommends coaching only to those individuals who need it most (i.e., those 
showing signs of early non-response). Hence, it is hypothesized that AI #1 is non-inferior in terms 
of long-term (month 6) weight loss compared to AI #3.  
Selecting the non-inferiority margin is the most critical and challenging step in non-
inferiority testing. The smaller the selected margin, the more difficult it is to establish non-
inferiority. Given that the non-inferiority margin provides scientific credibility to the test, it should 
be selected carefully based on relevant evidence, as well as sound clinical, practical, and/or ethical 
considerations. Extant literature on non-inferiority testing provides various guidelines for the 
selection of the non-inferiority margin (e.g., Walker & Nowacki, 2011; Lakens, 2017). With 
respect to the SMART weight loss study, based on relevant evidence (Ross & Wing, 2016) and 
established guidelines (Mohr et al, 2012), the non-inferiority margin is selected to be 50% of the 
difference found between similar intervention approaches. In this case 50% of 11.24 lb is 5.62 lb. 
Hence, the non-inferiority of AI #1 in relation to AI #3 will be established if the data provide 
sufficient evidence to conclude that on average the advantage of AI #3 (in terms of weight loss by 
month 6) compared to AI #1 does not exceed 5.62 lb.  
A related testing framework in randomized trials is that of equivalence tests (Seaman & 
Serlin, 1998; Goertzen & Cribbie, 2010; Walker & Nowacki, 2011; Lakens, 2017). In equivalence 
testing, one aims to test the hypothesis that a particular intervention is neither superior nor inferior 
to another intervention, subject to a pre-specified equivalence margin. The equivalence margin 
defines a range of values for which the expected outcomes are “close enough” to be considered 
equivalent. The equivalence of a new intervention is established when the data provide enough 
evidence to conclude that its efficacy is “close enough” (i.e., neither higher nor lower) to that of 
the active control intervention. 
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Data Structure and Notation 
 Consider a SMART design where individuals are randomized at the first stage to one of 
two initial intervention options, namely App (denoted by 𝑎𝑎) and App + Coaching (denoted by 
𝑎𝑎𝑎𝑎) as in Figure 2. Based on the individual’s progress during the first intervention stage, s/he can 
be classified as either a responder (𝑅𝑅 = 1) or a non-responder (𝑅𝑅 = 0). At the second stage, 
responders are allowed to continue with the same initial intervention option, whereas non-
responders are re-randomized to one of two second-stage options: modest augmentation (denoted 
by 𝑚𝑚) or vigorous augmentation (denoted by 𝑣𝑣). As can be seen in Figure 2 (also listed in Table 
1), four AIs are embedded in this SMART: 𝑑𝑑1 = (𝑎𝑎,𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅) , 𝑑𝑑2 = (𝑎𝑎,𝑎𝑎𝑅𝑅𝑚𝑚1−𝑅𝑅) , 𝑑𝑑3 =(𝑎𝑎𝑎𝑎, 𝑎𝑎𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅), and 𝑑𝑑4 = (𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝑅𝑅𝑚𝑚1−𝑅𝑅), where for example, 𝑑𝑑1  is an AI that recommends 
offering intervention option 𝑎𝑎 initially to all target individuals, and then continue offering the 
same treatment for individuals who show early signs of response, while offering intervention 
option 𝑣𝑣 to those showing early signs of non-response. For clarity in comparing embedded AIs, 
we classify any pair of embedded AIs under comparison to be either (1) distinct-path (DP): those 
starting with different initial interventions (e.g., {𝑑𝑑1,𝑑𝑑3} or {𝑑𝑑1,𝑑𝑑4} or {𝑑𝑑2,𝑑𝑑3} or {𝑑𝑑2,𝑑𝑑4}) or 
(2) shared-path (SP): those starting with the same initial intervention (e.g., {𝑑𝑑1,𝑑𝑑2} or {𝑑𝑑3,𝑑𝑑4}) 
(Kidwell & Wahed, 2013). 
Here, we assume a single continuous primary outcome 𝑌𝑌 (e.g., the amount of weight loss) 
observed at the end of the trial. Let 𝑇𝑇1 and 𝑇𝑇2 generically denote the intervention options at 
stages 1 and 2. Then the observed data trajectory for the 𝑖𝑖𝑡𝑡ℎ individual in a SMART is given by (𝑇𝑇1𝑖𝑖,𝑅𝑅𝑖𝑖,𝑇𝑇2𝑖𝑖,𝑌𝑌𝑖𝑖), 𝑖𝑖 = 1,⋯ ,𝑁𝑁, where 𝑁𝑁 is the total number of individuals in the trial. Since the 
distribution of the primary outcome is indexed by the sequences of intervention options received, 
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we write an individual's potential outcomes (Robins, 1997) as 𝑌𝑌𝑇𝑇1,𝑇𝑇2 where 𝑇𝑇1 ∈ {𝑎𝑎,𝑎𝑎𝑎𝑎};𝑇𝑇2 ∈{𝑎𝑎,𝑚𝑚, 𝑣𝑣} if 𝑇𝑇1 = 𝑎𝑎; and 𝑇𝑇2 ∈ {𝑎𝑎𝑎𝑎,𝑚𝑚, 𝑣𝑣} if 𝑇𝑇1 = 𝑎𝑎𝑎𝑎. Then we assume  
 𝐸𝐸(𝑌𝑌𝑇𝑇1,𝑇𝑇2) = 𝜇𝜇𝑇𝑇1,𝑇𝑇2    𝑎𝑎𝑎𝑎𝑑𝑑   𝑉𝑉𝑎𝑎𝑉𝑉(𝑌𝑌𝑇𝑇1,𝑇𝑇2) = 𝜎𝜎2, (1) 
which states that the mean outcome of all the individuals who were assigned the interventional 
sequence {𝑇𝑇1,𝑇𝑇2} is 𝜇𝜇𝑇𝑇1,𝑇𝑇2 and the corresponding variance is 𝜎𝜎2 (same for all the intervention 
sequences). Furthermore, the usual assumptions about potential outcomes (Robins, 1997) in a 
longitudinal setting, namely, (i) consistency, (ii) no unmeasured confounding and (iii) positivity 
are assumed to hold. Specifically, the consistency assumption states that the potential outcome 
under the observed treatment (sequence) and the observed outcome agree, i.e., 𝑌𝑌 = 𝑌𝑌𝑇𝑇1,𝑇𝑇2 if the 
observed treatment sequence is indeed (𝑇𝑇1,𝑇𝑇2) . The consistency assumption encompasses 
Rubin’s (1980) stable unit treatment value assumption (SUTVA) that says each participant’s 
potential outcome is not influenced by the treatment administered to the other participants 
(Chakraborty and Murphy, 2014). The no unmeasured confounding assumption states that 
treatment allocation is independent of future potential outcomes given the history; this is satisfied 
by design in case of a SMART (Murphy, 2005). Finally, the positivity assumption ensures that an 
individual has a positive probability of receiving any of the treatment sequences considered in the 
study. In other words, by positivity assumption, at least some individuals obtain each of the 
possible treatment sequences (AIs) feasible in the study. 
For both the non-inferiority and the equivalence test procedures, the test statistic is based 
on the means of the embedded AIs. By design, the mean of an AI is a weighted average of primary 
outcomes of patients having treatment trajectories consistent with that AI (Oetting et al., 2011; 
Nahum-Shani et al., 2012a). Intuitively, a weighted average is essential as there is a structural 
imbalance between responders and non-responders. In the two-stage SMART considered here, 
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non-responders are re-randomized at the second stage, but responders continue with the same 
treatment. Define the first-stage randomization probability in favor of intervention option 𝑇𝑇1 as 
𝜋𝜋𝑇𝑇1 , and the second-stage randomization probability for those who started with the first-stage 
option 𝑇𝑇1, in favor of intervention option 𝑇𝑇2 as 𝜋𝜋𝑇𝑇1,𝑇𝑇2 (often these probabilities are 0.5). Note 
that, 𝜋𝜋𝑎𝑎𝑎𝑎 = 1 − 𝜋𝜋𝑎𝑎 , 𝜋𝜋𝑎𝑎,𝑣𝑣 = 1 − 𝜋𝜋𝑎𝑎,𝑚𝑚  and 𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣 = 1 − 𝜋𝜋𝑎𝑎𝑎𝑎,𝑚𝑚 . A responder, due to a single 
randomization at stage 1, is assigned to the treatment sequence (𝑇𝑇1,𝑇𝑇1) with probability 𝜋𝜋𝑇𝑇1 (0.5 
in the case of the SMART weight loss study). On the other hand, due to two stages of 
randomization, a non-responder is assigned to a treatment sequence (𝑇𝑇1,𝑇𝑇2) with probability 
𝜋𝜋𝑇𝑇1 × 𝜋𝜋𝑇𝑇1,𝑇𝑇2 (0.5*0.5=0.25 in the case of the SMART weight loss study). Using the principles of 
inverse probability weighting (Robins, 1997; Nahum-Shani et al., 2012a), the weight used for the 
𝑖𝑖𝑡𝑡ℎ individual in any embedded AI 𝑑𝑑 is 1
𝜋𝜋𝑇𝑇1𝑖𝑖
 for a responder ( 1
0.5 = 2 in the case of responders 
in the SMART weight loss study) and 1
𝜋𝜋𝑇𝑇1𝑖𝑖×𝜋𝜋𝑇𝑇1𝑖𝑖,𝑇𝑇2𝑖𝑖 for a non-responder ( 10.25 = 4 in the case of 
the non-responders in the SMART weight loss study). In general, the weight can be expressed as 1/(𝜋𝜋𝑇𝑇1 × 𝜋𝜋𝑇𝑇1𝑖𝑖,𝑇𝑇2𝑖𝑖1−𝑅𝑅𝑖𝑖 ). Thus, the observed mean corresponding to the AI 𝑑𝑑1 can be written as  
 𝑌𝑌𝑑𝑑1 = ∑𝑁𝑁𝑖𝑖=1𝑊𝑊𝑖𝑖𝑑𝑑1𝑌𝑌𝑖𝑖∑𝑁𝑁𝑖𝑖=1𝑊𝑊𝑖𝑖𝑑𝑑1 ,   𝑤𝑤ℎ𝑒𝑒𝑉𝑉𝑒𝑒   𝑊𝑊𝑖𝑖𝑑𝑑1 = 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 , (2) 
where 𝐼𝐼{𝑇𝑇1𝑖𝑖 = 𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖} is an indicator for whether (=1) or not (=0) individual i is 
consistent with embedded AI 𝑑𝑑1  (i.e., the individual was assigned to 𝑎𝑎 initially, and then 
continued with 𝑎𝑎  if s/he was a responder or assigned to 𝑣𝑣  if s/he was a non-responder). 
Similarly, we can define other weights 𝑊𝑊𝑖𝑖
𝑑𝑑2 ,𝑊𝑊𝑖𝑖𝑑𝑑3  and 𝑊𝑊𝑖𝑖𝑑𝑑4  corresponding to the AIs 𝑑𝑑2,𝑑𝑑3 
and 𝑑𝑑4, respectively. Define 𝛾𝛾𝑇𝑇1 ∈ {𝛾𝛾𝑎𝑎, 𝛾𝛾𝑎𝑎𝑎𝑎} as the response rate to the initial intervention options 
𝑇𝑇1, with respect to some pre-specified definition of response (e.g., in the weight loss SMART, the 
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response is defined as losing at least 0.5 lb per week on average). Then the population mean of 
any embedded AI 𝑑𝑑 can be expressed as   
 𝜇𝜇𝑑𝑑 = 𝐸𝐸(𝑌𝑌𝑑𝑑) = 𝛾𝛾𝑇𝑇1𝜇𝜇𝑇𝑇1,𝑇𝑇1 + (1 − 𝛾𝛾𝑇𝑇1)𝜇𝜇𝑇𝑇1,𝑇𝑇2 , (3) 
 and the variance of the observed (sample) AI mean as  
 𝑉𝑉𝑎𝑎𝑉𝑉(?̂?𝜇𝑑𝑑) = 𝑉𝑉𝑎𝑎𝑉𝑉(𝑌𝑌𝑑𝑑) 
 = 1
𝑁𝑁
�
1−𝛾𝛾𝑇𝑇1+𝛾𝛾𝑇𝑇1𝜋𝜋𝑇𝑇1,𝑇𝑇2
𝜋𝜋𝑇𝑇1𝜋𝜋𝑇𝑇1𝑇𝑇2
𝜎𝜎2 + 𝛾𝛾𝑇𝑇1(1−𝛾𝛾𝑇𝑇1𝜋𝜋𝑇𝑇1)
𝜋𝜋𝑇𝑇1
𝜇𝜇𝑇𝑇1,𝑇𝑇12  
 + (1−𝛾𝛾𝑇𝑇1)(1−(1−𝛾𝛾𝑇𝑇1)𝜋𝜋𝑇𝑇1𝜋𝜋𝑇𝑇1,𝑇𝑇2)
𝜋𝜋𝑇𝑇1𝜋𝜋𝑇𝑇1,𝑇𝑇2 𝜇𝜇𝑇𝑇1,𝑇𝑇22 − 2𝛾𝛾𝑇𝑇1(1 − 𝛾𝛾𝑇𝑇1)𝜇𝜇𝑇𝑇1,𝑇𝑇1𝜇𝜇𝑇𝑇1,𝑇𝑇2}. (4) 
 When 𝜋𝜋𝑇𝑇1 = 𝜋𝜋𝑇𝑇1,𝑇𝑇2 = 12, then  
𝑉𝑉𝑎𝑎𝑉𝑉(?̂?𝜇𝑑𝑑) = 1𝑁𝑁 𝜎𝜎𝑑𝑑2  = 1
𝑁𝑁
{2(2 − 𝛾𝛾𝑇𝑇1)𝜎𝜎2 + 𝛾𝛾𝑇𝑇1(2 − 𝛾𝛾𝑇𝑇1)𝜇𝜇𝑇𝑇1,𝑇𝑇12 + (3 − 2𝛾𝛾𝑇𝑇1 − 𝛾𝛾𝑇𝑇12 )𝜇𝜇𝑇𝑇1,𝑇𝑇22 − 2𝛾𝛾𝑇𝑇1(1 −
𝛾𝛾𝑇𝑇1)𝜇𝜇𝑇𝑇1,𝑇𝑇1𝜇𝜇𝑇𝑇1,𝑇𝑇2}.
  (5) 
See Appendix A.1 and A.2 for a detailed derivation of the AI mean and corresponding variance, 
respectively. While developing the non-inferiority and equivalence test procedures in the context 
of a SMART, for simplicity, we consider 𝜋𝜋𝑎𝑎 = 𝜋𝜋𝑎𝑎𝑎𝑎 = 𝜋𝜋𝑎𝑎,𝑚𝑚 = 𝜋𝜋𝑎𝑎𝑎𝑎,𝑚𝑚 = 0.5. In other words, we 
assume that individuals are randomized with equal probability to first-stage intervention options, 
and non-responders as re-randomized with equal probability to second-stage intervention options.   
Non-Inferiority Test 
 The objective of a classical non-inferiority test is to show that the efficacy of a new 
intervention, when compared to an active control, is not below a pre-specified non-inferiority 
margin. A non-inferiority test becomes a traditional one-sided superiority test when the non-
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inferiority margin is set to zero. In this section, we describe the non-inferiority test procedure in 
the context of a SMART. For completeness, we consider the non-inferiority test for both distinct-
path and shared-path comparison of AIs. In general, for any two AIs 𝑑𝑑𝑖𝑖  and 𝑑𝑑𝑗𝑗  with 
corresponding means 𝜇𝜇𝑑𝑑𝑖𝑖 and 𝜇𝜇𝑑𝑑𝑗𝑗 , the null and alternative hypotheses for the non-inferiority test 
can be written as  
 𝐻𝐻0:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 ≥ 𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻1:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 < 𝜃𝜃, (6) 
where 𝜃𝜃 (> 0) is a pre-specified non-inferiority margin, and 𝑗𝑗 ≠ 𝑖𝑖 ∈ {1,⋯ ,4}. This hypothesis 
tests that the average efficacy of 𝑑𝑑𝑗𝑗 (the ‘new’ AI) is not inferior to that of 𝑑𝑑𝑖𝑖 (the control, or 
‘standard of care’ AI) with reference to the non-inferiority margin 𝜃𝜃. The unscaled test statistic is 
𝑌𝑌�𝑑𝑑𝑖𝑖 − 𝑌𝑌�𝑑𝑑𝑗𝑗. Intuitively, under the alternative, the difference in favor of the control AI (𝑑𝑑𝑖𝑖) is smaller 
than 𝜃𝜃, while under the null, this difference is equal to, or higher than 𝜃𝜃. As noted earlier, the 
margin 𝜃𝜃 represents the maximum clinically acceptable difference in favor of the control AI (𝑑𝑑𝑖𝑖) 
that an investigator is willing to accept in return for the secondary benefits (e.g., lower cost, burden 
and /or side effects) of the new AI (𝑑𝑑𝑗𝑗). The choice of the non-inferiority margin depends on both 
statistical reasoning and clinical judgment (D’Agostino, Massaro, & Sullivan, 2003). 
Comparison of Distinct-Path AIs 
 Let 𝜇𝜇𝑑𝑑1 and 𝜇𝜇𝑑𝑑3 be the means of the two distinct-path AIs, 𝑑𝑑1 and 𝑑𝑑3, respectively. 
Here we assume 𝑑𝑑3 to be the active control (or standard of care) AI. The goal is to test whether 
𝑑𝑑1 is non-inferior in efficacy to 𝑑𝑑3. From (6), the hypothesis of interest is  
𝐻𝐻0:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 ≥ 𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻1:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 < 𝜃𝜃.  
The unscaled test statistic is 𝑌𝑌𝑑𝑑3 − 𝑌𝑌𝑑𝑑1 , with population mean 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1, and variance 𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 =(𝜎𝜎𝑑𝑑32 + 𝜎𝜎𝑑𝑑12 )/𝑁𝑁 (see equation (5)), where  
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𝜎𝜎𝑑𝑑1
2 = 2(2 − 𝛾𝛾𝑎𝑎)𝜎𝜎2 + 𝛾𝛾𝑎𝑎(2 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑎𝑎2 + (3 − 2𝛾𝛾𝑎𝑎 − 𝛾𝛾𝑎𝑎2)𝜇𝜇𝑎𝑎,𝑚𝑚2 − 2𝛾𝛾𝑎𝑎(1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑎𝑎𝜇𝜇𝑎𝑎,𝑚𝑚, and 
𝜎𝜎𝑑𝑑3
2 = 2(2 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜎𝜎2 + 𝛾𝛾𝑎𝑎𝑎𝑎(2 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 + (3 − 2𝛾𝛾𝑎𝑎𝑎𝑎 − 𝛾𝛾𝑎𝑎𝑎𝑎2 )𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣2 − 2𝛾𝛾𝑎𝑎𝑎𝑎(1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣 
  (7).  
Thus, under 𝐻𝐻0, the large-sample distribution of the test statistic is  
 𝑍𝑍𝑑𝑑3𝑑𝑑1 = (𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1)−(𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1)
�𝑣𝑣𝑎𝑎𝑣𝑣(𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1) = 𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1−𝜃𝜃�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 → 𝑁𝑁(0,1). 
Thus, we reject 𝐻𝐻0 and conclude non-inferiority if 𝑍𝑍𝑑𝑑3𝑑𝑑1 < −𝑧𝑧𝛼𝛼 (one-sided test), where 𝛼𝛼 is 
the Type-I error rate and 𝑧𝑧𝛼𝛼 is the (1 − 𝛼𝛼)𝑡𝑡ℎ quantile of the standard normal distribution. Under 
a specified true mean difference 𝛿𝛿 such that 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1 = 𝛿𝛿, the required sample size is  
𝑁𝑁 = (𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2 �𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 �(𝜃𝜃−𝛿𝛿)2 =  2(𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2/�𝜂𝜂𝐷𝐷𝐷𝐷(θ) − 𝜂𝜂𝐷𝐷𝐷𝐷(δ)�2  = 2(𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2/𝜂𝜂𝐷𝐷𝐷𝐷2 , (8) 
where 𝛽𝛽  is the Type II error rate, 𝜂𝜂𝐷𝐷𝐷𝐷(θ)  =  𝜃𝜃
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑1
2 �/2  is the standardized margin, 
𝜂𝜂𝐷𝐷𝐷𝐷(δ)  = 𝛿𝛿
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑1
2 �/2 is the standardized mean difference, and 𝜂𝜂𝐷𝐷𝐷𝐷 =  𝜂𝜂𝐷𝐷𝐷𝐷(θ) − 𝜂𝜂𝐷𝐷𝐷𝐷(δ) =
𝜃𝜃−𝛿𝛿
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑1
2 �/2 is the overall standardized effect size for the comparison of two distinct-path AIs,. 
Furthermore, when 𝛿𝛿 = 0, 𝜂𝜂𝐷𝐷𝐷𝐷 boils down to the standardized margin. See Appendix A.3 for the 
derivation. Note that 𝑁𝑁 depends on the difference between the non-inferiority margin 𝜃𝜃 and the 
true mean difference 𝛿𝛿  rather than their individual values. Intuitively, 𝜃𝜃 − 𝛿𝛿  represents the 
discrepancy between the acceptable difference in favor of the control AI (𝑑𝑑3) that one is willing to 
accept in return for the secondary benefits (e.g., lower cost and participant burden) of the 
alternative AI (𝑑𝑑1), and the true mean difference in favor of 𝑑𝑑3 (i.e., 𝛿𝛿 ). The smaller that 
discrepancy, the larger the total sample size (𝑁𝑁) required to correctly establish non-inferiority with 
power 1-  𝛽𝛽 , given the selected Type-I error rate 𝛼𝛼 . The quantity 𝜂𝜂𝐷𝐷𝐷𝐷  is the standardized 
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difference between 𝜃𝜃 and 𝛿𝛿.  
 Comparison of Shared-Path AIs 
 Next, we consider two shared-path AIs 𝑑𝑑3 and 𝑑𝑑4 with corresponding means 𝜇𝜇𝑑𝑑3 and 
𝜇𝜇𝑑𝑑4. As before, consider 𝑑𝑑3 to be the active control (or standard of care) AI. However, now the 
goal is to investigate whether 𝑑𝑑4 is non-inferior to 𝑑𝑑3. Notice that both AIs start with the same 
initial intervention option (app + coaching), however, while 𝑑𝑑3 offers vigorous augmentation to 
non-responders in the form of text messaging and meal replacement, 𝑑𝑑4  offers modest 
augmentation in the form of text messaging alone. As in the distinct-path case, the unscaled test 
statistic is 𝑌𝑌𝑑𝑑3 − 𝑌𝑌𝑑𝑑4 with mean 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑4. However, in this case, the variance of the unscaled 
test statistic will be different from that of the distinct-path AIs, because the set of responders to the 
initial intervention (app + coaching) is consistent with both 𝑑𝑑3 and 𝑑𝑑4, thereby inducing some 
correlation between the two AIs. The variance of 𝑌𝑌𝑑𝑑3 − 𝑌𝑌𝑑𝑑4 is given by  
𝜈𝜈𝑑𝑑3𝑑𝑑4
𝑆𝑆𝐷𝐷 = 𝑉𝑉(?̂?𝜇𝑑𝑑3) + 𝑉𝑉(?̂?𝜇𝑑𝑑4) − 2𝑁𝑁 [𝛾𝛾𝑎𝑎𝑎𝑎𝜋𝜋𝑎𝑎𝑎𝑎 (𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 ) − (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚) ⋅(𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣)]  
 = 1
𝑁𝑁
(𝜎𝜎𝑑𝑑32 + 𝜎𝜎𝑑𝑑42 − 2𝜎𝜎𝑑𝑑3×𝑑𝑑42 ), (9) 
 where 1
𝑁𝑁
𝜎𝜎𝑑𝑑3×𝑑𝑑42 = 𝑎𝑎𝑐𝑐𝑣𝑣(?̂?𝜇𝑑𝑑3 , ?̂?𝜇𝑑𝑑4). See Appendix A.4 for the derivation. Therefore, under 𝐻𝐻0, the 
large-sample distribution of the test statistic is 
 𝑍𝑍𝑑𝑑3𝑑𝑑4 = (𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4)−(𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑4)
�𝑣𝑣𝑎𝑎𝑣𝑣(𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4) = 𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4−𝜃𝜃�𝜈𝜈𝑑𝑑3𝑑𝑑4𝑆𝑆𝐷𝐷 → 𝑁𝑁(0,1). 
Hence, we reject 𝐻𝐻0 and conclude non-inferiority if 𝑍𝑍𝑑𝑑3𝑑𝑑4 < −𝑧𝑧𝛼𝛼  (one-sided). Similar to the 
distinct-path case, under a specified true mean difference 𝛿𝛿  such that 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑4 = 𝛿𝛿 , the 
required sample size for the trial is  
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𝑁𝑁 = (𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2 �𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑42 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �(𝜃𝜃−𝛿𝛿)2  = =  2(𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2/�𝜂𝜂𝑆𝑆𝐷𝐷(θ) − 𝜂𝜂𝑆𝑆𝐷𝐷(δ)�2 = 2(𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2/
𝜂𝜂𝑆𝑆𝐷𝐷
2 , (10) 
where 𝜂𝜂𝑆𝑆𝐷𝐷 =  𝜂𝜂𝑆𝑆𝐷𝐷(θ) − 𝜂𝜂𝑆𝑆𝐷𝐷(δ) = 𝜃𝜃−𝛿𝛿
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑4
2 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �/2 is the standardized effect size for the 
comparison of two shared-path AIs. As in case of 𝜂𝜂𝐷𝐷𝐷𝐷, the standardized effect size 𝜂𝜂𝑆𝑆𝐷𝐷 is the 
difference between the standardized margin 𝜂𝜂𝑆𝑆𝐷𝐷(θ) = 𝜃𝜃
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑4
2 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �/2   and the 
standardized mean difference 𝜂𝜂𝑆𝑆𝐷𝐷(δ) = 𝛿𝛿
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑4
2 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �/2 . Note that, in the shared-path 
comparison of two AIs, only one response rate (e.g., in this case, that of the initial intervention 
𝑎𝑎𝑎𝑎) is involved. 
     Note that in real trials, there is always some degree of attrition; hence in order to maintain 
power the sample size (𝑁𝑁) needs to be inflated accordingly (in both distinct-path and shared-path 
scenarios).  
Standardized Effect Sizes 
It is important to note that even though we use the term standardized effect size here, the meaning 
of this effect size is different from Cohen’s d, as it does not quantify the standardized difference 
between two means alone, but rather the standardized difference between the non-inferiority 
margin and the true difference between the two means. Hence, the benchmark values 
recommended by Cohen do not directly apply. 
Furthermore, observe that for 𝜂𝜂𝐷𝐷𝐷𝐷  = 𝜂𝜂𝑆𝑆𝐷𝐷, the required sample sizes (N) are same for comparison 
of two distinct-path and two shared-path AIs. However, one should note that although the sample 
sizes are same, they may refer to different contexts of non-inferiority tests with different non-
inferiority margin and/or different mean difference of AIs. For example, consider a SMART 
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wherein the relevant embedded AIs have the following variances and covariance:  𝜎𝜎𝑑𝑑1
2 = 3,𝜎𝜎𝑑𝑑32 =5 ,𝜎𝜎𝑑𝑑42 =  4 and 𝜎𝜎𝑑𝑑3×𝑑𝑑42  =  0.5. For distinct-path comparison of AIs {d1, d3} with θDP = 1.4  and δDP = 1 , the 𝜂𝜂𝐷𝐷𝐷𝐷  is 0.2. On the other hand, for shared-path comparison of AIs {d3, d4}  with θSP =  2.8  and δSP = 2.4 , the 𝜂𝜂𝑆𝑆𝐷𝐷  is also 0.2. Thus, in both scenarios, the 
required sample size is 268. However, the key contextual parameters like the underlying 
standardized margin and standardized mean difference are different. One can claim that a 
particular SMART is powered for both distinct-path and shared-path comparisons only if it is 
acceptable to assume two different standardized margins for the two comparisons within the same 
SMART, which is unlikely the case in real life. Therefore, an investigator should first decide on 
the primary mode of comparison (distinct-path vs. shared-path) and determine the key context 
parameters (standardized margin, postulated standardized mean difference) before moving to the 
power/sample size calculation based on the standardized effect size derived from the above key 
context parameters. The same cautionary note applies to the equivalence tests discussed below. 
 
 
Equivalence Test 
As mentioned earlier, the term equivalence means that the efficacies of the two 
interventions under comparison are close to each other in a way that cannot be considered superior 
or inferior. Similar to the non-inferiority margin, here we consider an equivalence margin to define 
the closeness of two interventions. An equivalence test becomes a traditional two-sided superiority 
test when the equivalence margin is set to zero. An equivalence margin (−𝜃𝜃, 𝜃𝜃) is defined at the 
beginning of a trial such that any value in that range is clinically unimportant. After the trial, an 
equivalence is achieved if the estimated confidence interval of the treatment difference falls within 
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(−𝜃𝜃, 𝜃𝜃) (Ebbutt & Frith, 1998). In general, for any two AIs 𝑑𝑑𝑖𝑖  and 𝑑𝑑𝑗𝑗  with corresponding 
means 𝜇𝜇𝑑𝑑𝑖𝑖 and 𝜇𝜇𝑑𝑑𝑗𝑗 , the null and alternative hypotheses for the equivalence test are specified as  
 𝐻𝐻0:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 ≥ 𝜃𝜃   𝑐𝑐𝑉𝑉    𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 ≤ −𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻1:−𝜃𝜃 <  𝜇𝜇𝑑𝑑𝑖𝑖 − 𝜇𝜇𝑑𝑑𝑗𝑗 < 𝜃𝜃,  (11) 
where 𝜃𝜃 (> 0)  is a pre-specified equivalence margin. The above test actually contains two 
separate sub-tests: (1) a non-inferiority test ( 𝐻𝐻01:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 ≥ 𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻11:𝜃𝜃 < 𝜇𝜇𝑑𝑑𝑖𝑖 − 𝜇𝜇𝑑𝑑𝑗𝑗 < 𝜃𝜃) and (2) a non-superiority test (𝐻𝐻02:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 ≤ −𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻12:  𝜇𝜇𝑑𝑑𝑖𝑖 −  𝜇𝜇𝑑𝑑𝑗𝑗 >
−𝜃𝜃). In traditional RCTs, due to ease of use and recommendation from the United States Food and 
Drug Administration (FDA), a two one-sided tests (TOST) procedure is widely used for 
equivalence tests (Schuirmann, 1987; Lauzon & Caffo, 2009). Note that, in a TOST, two one-sided 
tests are considered, each of which having Type-I error rate 𝛼𝛼. Even though in order to achieve 
equivalence, both sub-tests require to reject the corresponding null hypotheses, the overall Type-I 
error rate of the TOST procedure is still 𝛼𝛼 , because only one of the two null hypotheses 
corresponding to the two sub-tests can be true at any one point of time. We further illustrate this 
point using simulation studies; see results presented in Tables 6 and 7 below. However, it turns 
out that a TOST procedure is operationally identical to the procedure of declaring equivalence if 
the ordinary (1 - 2α) x100% confidence interval (CI) for the mean difference of two AIs is 
completely contained in the equivalence margin (-θ, θ) (Schuirmann, 1987). In this section, we 
develop an equivalence test procedure for SMART, separately for the distinct-path and the shared-
path AIs. 
Comparison of Distinct-Path AIs 
 First, we consider the non-inferiority sub-test of an equivalence test for distinct-path AIs. 
For the two distinct-path AIs 𝑑𝑑1 and 𝑑𝑑3 with respective means 𝜇𝜇𝑑𝑑1  and 𝜇𝜇𝑑𝑑3 , we repeat the 
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non-inferiority test procedure described in the previous section. The same test statistic 𝑍𝑍𝑑𝑑3𝑑𝑑1 is 
used to test 𝐻𝐻01:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 ≥ 𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻11:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 < 𝜃𝜃 . The null hypothesis 𝐻𝐻01 
will be rejected if 𝑍𝑍𝑑𝑑3𝑑𝑑1 < −𝑧𝑧𝛼𝛼.  
For the non-superiority sub-test 𝐻𝐻02:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 ≤ −𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻12:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑1 >
−𝜃𝜃, the large-sample distribution of the test statistic under 𝐻𝐻02 is  
 𝑍𝑍𝑑𝑑3𝑑𝑑1
∗ = (𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1)−(𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1)
�𝑣𝑣𝑎𝑎𝑣𝑣(𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1) = 𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1+𝜃𝜃�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 → 𝑁𝑁(0,1). 
Notice that, 𝑍𝑍𝑑𝑑3𝑑𝑑1
∗  is different from 𝑍𝑍𝑑𝑑3𝑑𝑑1 with respect to the sign of 𝜃𝜃 in their expressions. 
Reject 𝐻𝐻02 and conclude non-superiority if 𝑍𝑍𝑑𝑑1𝑑𝑑3
∗ > 𝑧𝑧𝛼𝛼. Finally, we conclude equivalence when 
both tests reject the corresponding null hypotheses. Given a postulated true mean difference 𝛿𝛿 =
𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1 ≠ 0 , there is no closed-form solution for the minimum required sample size (𝑁𝑁 ). 
However, the power of the equivalence test is given by  
    Φ�−𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� −Φ�𝑧𝑧𝛼𝛼 −
𝜃𝜃+𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� 
 =  Φ�−𝑧𝑧𝛼𝛼 + (𝜂𝜂𝐷𝐷𝐷𝐷(θ)− 𝜂𝜂𝐷𝐷𝐷𝐷(δ))�𝑁𝑁2� − Φ�𝑧𝑧𝛼𝛼 − (𝜂𝜂𝐷𝐷𝐷𝐷(θ) + 𝜂𝜂𝐷𝐷𝐷𝐷(δ))�𝑁𝑁2�, (12) 
where the standardized margin 𝜂𝜂𝐷𝐷𝐷𝐷(θ) =  𝜃𝜃
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑1
2 �/2,  the standardized mean difference 
𝜂𝜂𝐷𝐷𝐷𝐷(δ) = 𝛿𝛿
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑1
2 �/2  and  Φ(𝑥𝑥) denotes the cumulative distribution function of a standard 
normal variable evaluated at a point 𝑥𝑥. See Appendix A.5 for the derivation. The formula in (12) 
can be used to estimate the power corresponding to a particular sample size (𝑁𝑁) when all the 
involved parameters are known. Repeating the procedure to estimate the power corresponding to 
different 𝑁𝑁 leads to an iterative procedure to derive the required sample size corresponding to a 
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desired power. Note that, unlike the comparison of distinct-path AIs in the non-inferiority setting, 
here the sample size based on expression (12) depends on the individual values of 𝜃𝜃 and 𝛿𝛿, as 
opposed to their difference 𝜃𝜃 − 𝛿𝛿 alone.  
    In the special case when the postulated true mean difference 𝛿𝛿 = 0, the minimum sample 
size has a closed form and is given by  
 𝑁𝑁 = �𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽/2�2 (𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 )𝜃𝜃2 = 2�𝑧𝑧𝛼𝛼+𝑧𝑧𝛽𝛽2�2𝜂𝜂𝐷𝐷𝐷𝐷2 (θ) . (13) 
Comparison of Shared-Path AIs 
 In an equivalence test procedure to compare two shared-path AIs 𝑑𝑑3 and 𝑑𝑑4, as before, 
we first focus on the non-inferiority sub-test described above. The test statistic 𝑍𝑍𝑑𝑑3𝑑𝑑4 is used to 
test 𝐻𝐻01:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑4 ≥ 𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻11:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑4 < 𝜃𝜃 . The null hypothesis 𝐻𝐻01  will be 
rejected if 𝑍𝑍𝑑𝑑3𝑑𝑑4 < −𝑧𝑧𝛼𝛼 . For the non-superiority sub-test 𝐻𝐻02:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑4 ≤
−𝜃𝜃   𝑣𝑣𝑣𝑣.   𝐻𝐻12:  𝜇𝜇𝑑𝑑3 −  𝜇𝜇𝑑𝑑4 > −𝜃𝜃, the large-sample distribution of the test statistic under 𝐻𝐻02 
is  
 𝑍𝑍𝑑𝑑3𝑑𝑑4
∗ = (𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4)−(𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑4)
�𝑣𝑣𝑎𝑎𝑣𝑣(𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4) = 𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑4+𝜃𝜃�𝜈𝜈𝑑𝑑3𝑑𝑑4𝑆𝑆𝐷𝐷 → 𝑁𝑁(0,1). 
We reject 𝐻𝐻02 and conclude non-superiority if 𝑍𝑍𝑑𝑑3𝑑𝑑4
∗ > 𝑧𝑧𝛼𝛼. As in the distinct-path scenario, we 
conclude equivalence when both sub-tests reject the corresponding null hypotheses. The power of 
the test for a given 𝑁𝑁  can be obtained from the expression (12) with 𝜂𝜂𝐷𝐷𝐷𝐷(θ)  and 
𝜂𝜂𝐷𝐷𝐷𝐷(δ) replaced by 𝜂𝜂𝑆𝑆𝐷𝐷(θ) and η𝑆𝑆𝐷𝐷(δ), respectively, where the standardized margin 𝜂𝜂𝑆𝑆𝐷𝐷(θ) = 𝜃𝜃
��𝜎𝜎𝑑𝑑3
2 +𝜎𝜎𝑑𝑑4
2 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �/2 and the standardized mean difference η𝑆𝑆𝐷𝐷(δ) =  𝛿𝛿��𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑42 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �/2. 
To estimate the minimum required sample size when the postulated true mean difference 𝛿𝛿 ≠ 0, 
one can compute the power for a series of 𝑁𝑁 until ones finds a suitable 𝑁𝑁 corresponding to a 
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desired power.  
      Finally, in the special case of 𝛿𝛿 = 0, the minimum sample size is given by  
 𝑁𝑁 = �𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽/2�2 �𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑42 −2𝜎𝜎𝑑𝑑3×𝑑𝑑42 �𝜃𝜃2 = 2�𝑧𝑧𝛼𝛼+𝑧𝑧𝛽𝛽2�2𝜂𝜂𝑆𝑆𝐷𝐷2 (θ) . (14) 
Simulation Studies 
 In this section, we discuss simulation studies conducted to: (a) investigate how the Monte 
Carlo (MC) power varies with the standardized effect size (𝜂𝜂) and the sample size (𝑁𝑁), when the 
margin (𝜃𝜃) is fixed, by studying power curves; (b) empirically assess the performance of the 
sample size formulas in both non-inferiority and equivalence tests when the nominal power is fixed 
at 80%; (c) check the robustness of our sample size formula to the key working assumption of 
equal variance across various intervention sequences; and (d) illustrate the control of Type I error 
rate at or below the nominal 5% level under the TOST procedure employed in equivalence testing. 
The R-codes related to the simulation studies are available in Open Science Framework 
(https://osf.io/hwae3/).  
 
Simulation Design  
The data generation process and the various required parameter values under all the 
simulation scenarios are given in the Appendix (section A.6 and Table 1).  
For the first goal of studying power curves, we do not calculate N from the sample size 
formulas, but rather set N to specific values (e.g., N = 100, 200, 300 or 500). For illustration 
purpose, we set the non-inferiority/equivalence margin 𝜃𝜃 = 2. Then, for varying standardized 
effect sizes, we generate 1000 simulated SMART datasets with the same size N. Next, for each of 
the 1000 datasets, we calculate the test statistic, and depending on its value, either reject or accept 
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the null hypothesis. Finally, we calculate the MC power as the percentage of tests for which the 
null hypothesis is rejected. For example, if the null hypothesis is rejected in 810 out of the 1000 
tests, then the MC power is 81%. In the power curves, the horizontal axis corresponds to 
standardized effect size and the vertical axis corresponds to estimated power.  
For the second goal of assessing the adequacy of the sample size formulas, we first set the 
Type I error rate at 5%, the desired power at 80%, and the standardized effect size at a fixed value 
(e.g., 0.3). Next, we use these parameters to calculate the required sample size based on the relevant 
sample size formula, namely, equation (8), (10), (13) or (14), depending on whether the focus is 
on non-inferiority/equivalence testing and distinct-path/shared-path comparison. For example, in 
the case of a non-inferiority distinct-path comparison, the calculated N for a 0.3 standardized effect 
size with 80% power and 5% type I error rate is 138. Then, based on the calculated N (e.g., N=138) 
we generate 1000 simulated SMART datasets with the same size; thereafter for each of the 1000 
datasets, we calculate the test statistic and either reject or accept the null hypothesis based on its 
value. Finally, as in the case of studying power curves, we calculate the MC power as the 
percentage of the tests for which the null hypothesis is rejected. An estimated MC power close to 
the nominal value of 80% indicates that the sample size formula is adequate. 
The third goal of checking the robustness of our sample size formulas to the key working 
assumption of equal variance across various intervention sequences (see equation (1)) is 
operationally similar to the second goal described above. Here we calculate a robust version of 
MC power (𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡) using 1000 simulated datasets following the same steps as above, but 
the data generation is slightly different. Specifically, in any given simulation scenario, we first 
determine the total required sample size 𝑁𝑁 of the SMART based on the relevant formula; then 
for each possible intervention sequence {𝑇𝑇1,𝑇𝑇2} in that SMART, we generate 𝑁𝑁𝑇𝑇1,𝑇𝑇2 number of 
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observations on the primary outcome 𝑌𝑌 from 𝑁𝑁(𝜇𝜇𝑇𝑇1,𝑇𝑇2 ,σT1T22 ) such that ∑ 𝑁𝑁𝑇𝑇1,𝑇𝑇2𝑇𝑇1,𝑇𝑇2 = 𝑁𝑁, where 
σ𝑇𝑇1,𝑇𝑇2 is a random number generated from the uniform distribution (max(0.5,σ −  1), σ + 1), 
with σ being the assumed common standard deviation across all the intervention sequences. 
Thus, even though our working assumption for the sample size formula takes the variances across 
the intervention sequences to be equal, the data here are generated under different variances. 
Hence, a value of the robust version of power (𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡) close to the nominal power of 80% 
would establish the robustness of our sample size formulas.      
For the fourth goal of illustrating the control of Type I error rate at or below the nominal 5% 
level under the TOST procedure employed in equivalence testing, we first determine the required 
sample sizes based on our formulas and then generate data when there is no true effect. Based on 
similar Monte Carlo technique as described above, we assess the rejection rates of the equivalence 
test. We also investigate additional sample sizes in the range 500-5000.  
 
Results 
In Figure 3, we present the power curves for both the distinct-path and the shared-path 
settings in non-inferiority and equivalence tests based on MC simulations. As expected, given a 
fixed standardized effect size (𝜂𝜂), the power increases as the sample size increases from 100 to 
500, for all the four scenarios. For a given 𝜂𝜂, the amount of increase in power is substantial for a 
change in the sample size from 100 to 200, compared to the change in the sample size from 200 to 
300 or from 300 to 500. The power curve representation conveys a requirement of samples in the 
range of 100-200 in order to detect a standardized effect size in the range of 0.4 to 0.2, respectively. 
In case of equivalence tests, the power curves become gradually symmetric when the sample size 
increases from 100 to 500; however, for small trial sizes, the small number of samples in each 
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experimental subgroup results in deviation from approximate normality of AI means, which in 
turn results in the slight asymmetry in the power curves. 
In Table 2, we focus on a non-inferiority test involving the comparison of two distinct-path 
AIs 𝑑𝑑1  and 𝑑𝑑3 , wherein 𝑁𝑁  represents the required sample size calculated from the relevant 
sample size formula, and 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  is the corresponding MC power. Note that the highest 
standardized effect size 𝜂𝜂𝐷𝐷𝐷𝐷 in Table 2 is 0.379 with corresponding sample size 𝑁𝑁 = 87. We do 
not choose any higher standardized effect size in order to avoid small sample sizes (say, less than 
80), because a SMART design with fewer than 80 samples may end up with very few individuals 
for some intervention sequences. In Table 2, the 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  values range from 0.79 to 0.84. The 
required sample size 𝑁𝑁 is a decreasing function of 𝜂𝜂𝐷𝐷𝐷𝐷, as expected. The value of the margin is 
also varied in our study, 𝜃𝜃 ∈ {2.5, 3.0}. A smaller value of 𝜃𝜃 results in a smaller standardized 
effect size, which in turn increases the required sample size.  
Similarly, in Table 3, we focus on a non-inferiority test involving the comparison of two 
shared-path AIs 𝑑𝑑4 and 𝑑𝑑3. Here we consider only one (shared) response rate 𝛾𝛾𝑎𝑎𝑎𝑎. In Table 3, 
the 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  values range from 0.77 to 0.84. As expected, the required sample size 𝑁𝑁  is a 
decreasing function of the corresponding standardized effect size. 
The last columns in both Tables 2 and 3 show the estimated robust power (𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡) 
values, where the data generation violates the working assumption of equal variance across 
intervention sequences. These values range between 0.79 and 0.82 in Table 2 and between 0.76 
and 0.84 in Table 3, and are either same or close to the corresponding 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  values, thereby 
establishing the robustness of our proposed sample size formulas.  
As explained earlier, in an equivalence test, there is no closed-form expression of the 
required sample size in general; however, in the special case when 𝛿𝛿 = 0, the sample size can be 
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written in a closed form. In Tables 4 and 5, we present simulation results from equivalence tests 
in distinct-path and shared-path comparisons of two AIs, respectively. Here we assume 𝛿𝛿 =
𝛿𝛿𝐷𝐷𝐷𝐷 = 𝛿𝛿𝑆𝑆𝐷𝐷 = 0 and 𝛾𝛾𝑎𝑎 = 𝛾𝛾𝑎𝑎𝑎𝑎 = 𝛾𝛾. From Tables 3 and 4, clearly the required sample size 𝑁𝑁 is a 
decreasing function of 𝛾𝛾 for both the distinct-path and the shared-path comparisons. In Table 4 
(distinct-path comparison), the 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  values range from 0.82 to 0.84; likewise, in Table 5 
(shared-path comparison), the 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  values range from 0.83 to 0.86.  
In Tables 6 and 7, we have verified that the Type-I error rate is controlled at or below 5% 
(for nominal 𝛼𝛼 = 0.05) when there is no effect. In both tables, the respective sample sizes 244 
and 175 in the first rows are based on the sample size formula for the equivalence test when 𝛿𝛿 = 𝛿𝛿𝐷𝐷𝐷𝐷 =  𝛿𝛿𝑆𝑆𝐷𝐷 = 0. Other values of N, 500-5000, are provided when the standardized effect sizes 
0.265 and 0.313 are fixed in Tables 6 and 7, respectively. The estimate Type-I error rates in both 
the tables establish our claim that the Type I error rate is controlled at or below 5% when there is 
no effect even with increasing sample sizes. 
Discussion 
Non-inferiority and equivalence tests are widely used in traditional randomized controlled 
trials (RCTs) to establish the non-inferiority or the equivalence of one intervention, which has 
some secondary benefit (e.g. less costly or less burdensome), over the other. Blackwelder (1982) 
gave a detailed discussion on the inappropriate use of the usual null hypothesis to show that a new 
therapy was as effective as a standard therapy. The roles of the null and alternative hypotheses 
(hence the Type-I and Type-II error rates) are reversed from traditional superiority test to a non-
inferiority (and equivalence) test. An investigator should take note of this reversal when 
interpreting results from a non-inferiority/equivalence test. 
We motivated the need for non-inferiority and equivalence tests for SMARTs by 
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considering an example from the SMART weight loss study. We have developed data analytic 
methods and sample size formulas for SMART studies with primary scientific questions 
concerning the non-inferiority or equivalence of one adaptive intervention (AI) over another. The 
simulation studies demonstrate the adequacy of the sample size formulas. The estimated power 
(based on MC simulations) came out to be very close to the nominal value of 80% in all scenarios. 
The developed methodologies can handle situations in which the AIs under comparison begin with 
different intervention options (i.e., distinct-path) and also in which they begin with the same 
intervention option (i.e., shared-path). We illustrate the usefulness of our methodology in 
analyzing SMART data to conclude non-inferiority/equivalence among AIs through simulated 
data analyses in the Appendix (see section A.7 and Appendix Table 2). 
The simulation studies also demonstrate the practical feasibility of testing non-inferiority 
and equivalence with data arising from SMARTs, given the realistic sample sizes needed to 
achieve adequate power. SMARTs enrolling 200-700 participants are highly common. For 
example, both the Adapt RBT SMART for developing an adaptive reinforcement-based treatment 
for pregnant women who are drug dependent (H. Jones, PI; NIH/NIDA R01DA014979; see Lei, 
Nahum-Shani, Lynch, Oslin, & Murphy, 2012) and the ExTENd SMART for extending treatment 
effectiveness of naltrexone (D. Oslin, PI, NIH/NIAAA; NIAAAOSL01485; see Nahum-Shani et 
al., 2017) enrolled about 300 participants, the ENGAGE SMART study for engaging cocaine-
dependent individuals in treatment services (McKay et al., 2015) enrolled 500 participants, and 
the PLUTO SMART (Fu et al., 2017) for lung cancer screening and tobacco cessation (PLUTO) 
enrolled 1,000 participants. In this light, SMART with sample size in the range 50-200 may be 
considered a small SMART. 
The methods described in the current manuscript are motivated by various SMART studies, 
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including the SMART Weight Loss study that we have used throughout for illustration. Given 
resource limitations, many SMART studies (see Lei et al., 2012) seek to inform the construction 
of stepped-care adaptive interventions (Sobell & Sobell, 2000), whereby minimal support 
(consisting of relatively low burden and/or low-cost intervention options) is offered initially, and 
more burdensome/costly interventions are reserved for those who need it most (i.e., those who do 
not respond adequately to minimal support). In this context, testing non-inferiority or equivalence 
of one embedded AI (e.g., the less costly/burdensome) over another (e.g., an AI that represents a 
more costly/burdensome standard of care) is logical and practically meaningful. In fact, in the 
current era of fast technological advancements, there is increasing interest in developing stepped-
care behavioral interventions that use mHealth tools as minimal support. mHealth interventions 
capitalize on mobile and/or wireless devices to deliver behavioral interventions in a relatively low 
cost, low burden, and accessible manner (Kumar et al., 2013). The use of SMART studies to 
investigate the optimal way to integrate mHealth tools with more traditional intervention 
components in order to achieve more cost-effective and scalable intervention programs often 
necessitates non-inferiority and equivalence testing frameworks. For example, the justification for 
initiating treatment by offering a new mHealth tool (e.g., weight loss app) instead of a more 
costly/burdensome traditional intervention component (e.g., coaching or in-person sessions) 
requires demonstrating that the weight loss generated by an AI that integrates the new mHealth 
tool is only marginally lower than the more costly/burdensome traditional approach.  
Whether the SMART should be sized for non-inferiority or equivalence depends on the 
scientific questions motivating the trial. Non-inferiority is used when the primary objective is to 
demonstrate that the novel approach (e.g., an AI that integrates low-cost or low-burden 
components such as mHealth tools) is not worse than an active control intervention (e.g., an AI 
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that offers more costly/burdensome components throughout). In this case, the novel intervention 
is expected to be only marginally less beneficial (and possibly even more beneficial) than the active 
control intervention. Equivalence is used when the primary objective is to demonstrate that the 
novel intervention is neither worse nor better than the active control. Equivalency designs are 
rarely used in randomized trials aiming to construct or evaluate less costly/burdensome behavioral 
interventions because their typical objective is to show that the effectiveness of a new intervention 
is only marginally lower (i.e., non-inferior), as opposed to similar (i.e., equivalence) compared to 
the standard of care (Greene, Morland, Durkalski, & Frueh, 2008). 
A SMART can have one (or multiple) primary hypothesis and multiple secondary 
hypotheses (Almirall et al., 2014). In an experimental trial, an investigator determines the required 
sample size based on the primary hypothesis (Piantadosi, 2005). However, s/he may have other 
secondary hypotheses which justify the inclusion of adaptive interventions (say, AI #2, AI # 4) 
other than main adaptive interventions of interest (say for distinct-path comparison: AI #1 vs. AI 
#3). However, not all the secondary hypotheses are necessarily adequately powered (Murphy, 
2005). Nonetheless, these secondary or exploratory aims are important in advancing science as it 
can facilitate preliminary insights to inform future studies or to generate new hypotheses.  
From an investigator’s point of view, an advantage of the developed methods is that the 
required sample size can be calculated only by specifying the standardized effect size ( as a 
function of standardized margin and the standardized mean difference), without having to specify 
additional parameters that are often difficult to elicit (e.g., variances). To make these methods 
accessible to investigators, we have developed freely available online tools (https://osf.io/z7av5/) 
using R statistical software. These tools allow investigators to plan sample size for SMART studies 
aiming to test the non-inferiority or equivalence of one embedded AI compared to another without 
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requiring any programming knowledge. They also allow investigators to analyze data from 
completed SMART studies to answer questions about non-inferiority and equivalence. 
Our entire methodology of non-inferiority/equivalence testing as presented in this article 
relies on the classical frequentist paradigm, which concludes non-inferiority/equivalence based on 
a pre-specified threshold (say, 0.05) of the corresponding p-values. To overcome this over-
dependence on the p-value cutoff in hypothesis testing, many researchers prefer a Bayesian 
analysis, and in particular, a quantification of evidence in favor of a hypothesis through a quantity 
called Bayes Factor. A full-fledged Bayesian analysis that needs to specify prior distributions for 
parameters under both the null and alternative hypotheses is beyond the scope of the current article. 
However, there exists a simple way to convert an observed p-value to construct an upper bound of 
the Bayes Factor; this bound is given by 1
− 𝑒𝑒 𝑝𝑝 log(𝑝𝑝), where 𝑝𝑝 denotes the p-value (Benjamin and 
Berger, 2016; Bayarri et al., 2016). The above upper bound is the largest possible value of the 
Bayes Factor over any (reasonable) choice of the prior distribution for the alternative hypothesis, 
and thus represents the maximum possible evidence in favor of the alternative hypothesis present 
in the data. Being a simple function of the p-value, it is easy to calculate. Also, it is an acceptable 
metric to both Bayesians and frequentists. While illustrating our non-inferiority/equivalence 
testing methodology through some simulated dataset in the Appendix, we also report the estimated 
upper bounds of the Bayes Factor in addition to the usual p-values (see Appendix section A.7 and 
Appendix Table 2). 
 
Limitations and Directions for Future Research  
The described methods in the current manuscript are based on the so-called restricted 
SMART wherein only one group of participants (e.g., non-responders to the first-stage 
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intervention) are re-randomized at the second stage. In principle, the developed methods, with 
some modification, can also be applied to other types of SMART designs discussed in the 
introduction. For example, in a SMART, when both the responders and non-responders from the 
first stage are re-randomized at the second stage, the mean and the variance formula of an AI can 
be derived from the same approach as in the Appendix, even though we have not explicitly done 
that. The rest of the developed procedures remain the same in the context of non-
inferiority/equivalence tests. 
In the current article, we have described the non-inferiority and equivalence testing 
framework with respect to continuous outcomes only. However, the same methodology can be 
easily extended to binary outcomes, following the work of Ghosh, Cheung, and Chakraborty 
(2016). For time-to-event outcomes, some additional work may be necessary to develop non-
inferiority/equivalence versions of the weighted log-rank tests considered by Kidwell and Wahed 
(2013). Some work can be done to extend the proposed methodology for longitudinal outcome 
data (to incorporate within-person correlation) and for clustered SMARTs (to incorporate 
intraclass correlation). 
The non-inferiority/equivalence margin 𝜃𝜃 is a key concept that formalizes the notion of 
"sufficiently close" in such trials. However, setting an appropriate value of 𝜃𝜃 remains a challenge. 
A margin that is too narrow may lead to unnecessarily large sample size requirements, whereas a 
margin that is too wide may end up establishing an equivalence for two interventions that are in 
fact substantially different. Information from recent clinical trials involving the standard treatment 
can provide useful guidelines for choosing an appropriate value of 𝜃𝜃 (D’Agostino et al., 2003). 
Further discussion of the selection of non-inferiority margin in an RCT can be found in Chow and 
Song (2016). In the context of SMARTs, if the treatment sequences consist of marketed drugs, 
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data from the corresponding phase-III trials can be used to choose a value of 𝜃𝜃. More in-depth 
thought about how to optimally set the value of 𝜃𝜃 is necessary in the SMART design context; we 
view this as an important future work. 
In this article, we have not considered a policy evaluation approach to find an optimal AI 
(Zhao et al., 2012, 2015a,b; Zhang et al., 2012; Logan  et al., 2017; Laber et al., 2018). In 
particular, Logan et al. (2017) use Bayesian Additive Regression Trees (BART) to model the 
conditional mean function of the outcome and to inform identification of an individualized 
treatment rule (ITR) and subsequently proposed a method to find the optimal ITR. A policy 
evaluation approach in the context of non-inferiority/equivalence tests will be exciting future work. 
Specifically, it would be interesting to find an optimal AI based on the individuals’ treatment and 
other covariates’ information among a finite set of non-inferior (equivalent) AIs.  
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Figure 1: An example adaptive intervention for promoting weight 
loss among obese/overweight adults 
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Figure 2: The SMART Weight Loss Management Study 
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Table 1. Adaptive Interventions Embedded in the Weight Loss SMART Study 
AIs Initial 
treatment 
Subsequent tactic (treatment) for 
non-responders (R=0) 
Subsequent 
tactic for 
responders 
(R=1) 
Subgroups 
in Figure 1 
Stage-specific 
treatments: 
(T1, T2) 
1 App 
(a) 
Vigorous Augmentation (v): add 
supportive text messaging and 
coaching 
 
Continue 
first-line 
intervention 
A+C (a, aRv1-R) 
2 App 
(a) 
Modest Augmentation (m): add 
supportive text messaging  
A+B (a, aRm1-R) 
3 App + 
coaching  
(ac) 
Vigorous Augmentation (v): add 
supportive text messaging and 
meal replacement  
D+F (ac, acRv1-R) 
4 App + 
coaching 
(ac) 
Modest Augmentation (m): add 
supportive text messaging 
D+E (ac, acRm1-R) 
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Table 2. Results of the non-inferiority test involving the distinct-path AIs {𝑑𝑑1,𝑑𝑑3}. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. 𝜃𝜃 is the non-inferiority margin. 𝛾𝛾𝑎𝑎 and 𝛾𝛾𝑎𝑎𝑎𝑎 are the response rates of initial treatments 𝑎𝑎 
and 𝑎𝑎𝑎𝑎, corresponding to the AIs 𝑑𝑑1 and 𝑑𝑑3 respectively; 𝜂𝜂𝐷𝐷𝐷𝐷 is the standardized effect size. 
The required sample size 𝑁𝑁 is calculated based on equation (8) and the estimated power (𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  
and 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡) is based on 1000 Monte Carlo simulations. 
 
 
 
 
 
  
 (𝛾𝛾𝑎𝑎, 𝛾𝛾𝑎𝑎𝑎𝑎)  𝜃𝜃 𝜂𝜂𝐷𝐷𝐷𝐷 𝑁𝑁 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡 
(0.30, 0.50) 3.0 0.379 87 0.82 0.81 
(0.30, 0.45) 3.0 0.371 90 0.80 0.80 
(0.30, 0.40) 3.0 0.362 95 0.82 0.82 
(0.30, 0.35) 3.0 0.354 99 0.82 0.81 
(0.30, 0.30) 3.0 0.347 103 0.79 0.81 
(0.30, 0.50) 2.5 0.251 197 0.80 0.79 
(0.30, 0.45) 2.5 0.243 210 0.81 0.81 
(0.30, 0.40) 2.5 0.236 223 0.80 0.80 
(0.30, 0.35) 2.5 0.230 234 0.79 0.81 
(0.30, 0.30) 2.5 0.223 249 0.84 0.82 
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Table 3. Results of the non-inferiority test involving the shared-path AIs {𝑑𝑑4,𝑑𝑑3} 
 
𝛾𝛾𝑎𝑎𝑎𝑎 𝜃𝜃 𝜂𝜂𝑆𝑆𝐷𝐷 𝑁𝑁 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡 
0.50 3.0 0.384 84 0.79 0.78 
0.45 3.0 0.345 104 0.78 0.78 
0.40 3.0 0.312 128 0.81 0.79 
0.35 3.0 0.281 157 0.84 0.84 
0.30 3.0 0.254 192 0.80 0.79 
0.50 2.5 0.252 195 0.77 0.76 
0.45 2.5 0.215 268 0.79 0.79 
0.40 2.5 0.184 366 0.79 0.79 
0.35 2.5 0.157 502 0.83 0.81 
0.30 2.5 0.130 732 0.82 0.82 
 
 
Note. 𝜃𝜃 is the non-inferiority margin.; 𝛾𝛾𝑎𝑎  is the response rate of the initial treatment 𝑎𝑎 that 
corresponds to both AIs 𝑑𝑑4 and 𝑑𝑑3 (the other initial response rate 𝛾𝛾𝑎𝑎𝑎𝑎 is set at 0.5); 𝜂𝜂𝑆𝑆𝐷𝐷 is the 
standardized effect size. The required sample size 𝑁𝑁 is calculated based on equation (10) and the 
estimated power (𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  and 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� 𝑣𝑣𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑡𝑡) is based on 1000 Monte Carlo simulations. 
 
 
 
 
 
 
56 
 
 
Table 4. Results of the equivalence test involving the distinct-path AIs {𝑑𝑑1,𝑑𝑑3} with 𝛿𝛿 = 𝜇𝜇𝑑𝑑3 −
𝜇𝜇𝑑𝑑1 = 0 
( 𝛾𝛾𝑎𝑎 , 𝛾𝛾𝑎𝑎𝑎𝑎 ) 𝜃𝜃 𝜂𝜂𝐷𝐷𝐷𝐷 𝑁𝑁 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  
(0.50, 0.50) 2.0 0.265 244 0.83 
(0.45, 0.45) 2.0 0.259 256 0.83 
(0.40, 0.40) 2.0 0.254 266 0.82 
(0.35, 0.35) 2.0 0.249 277 0.82 
(0.30, 0.30) 2.0 0.244 288 0.84 
 
Note. 𝜃𝜃 is the equivalence margin; 𝛾𝛾𝑎𝑎 and 𝛾𝛾𝑎𝑎𝑎𝑎 are the response rates of initial treatments 𝑎𝑎 
and 𝑎𝑎𝑎𝑎, corresponding to the AIs 𝑑𝑑1 and 𝑑𝑑3 respectively; 𝜂𝜂𝐷𝐷𝐷𝐷 is the standardized effect size. 
The required sample size 𝑁𝑁 is calculated based on equation (13) and the estimated power 
(𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� ) is based on 1000 Monte Carlo simulations. 
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Table 5: Results of the equivalence test involving the shared-path AIs {𝑑𝑑4,𝑑𝑑3} with 𝛿𝛿 = 𝜇𝜇𝑑𝑑3 −
𝜇𝜇𝑑𝑑4 = 0 
   
𝛾𝛾𝑎𝑎𝑎𝑎 𝜃𝜃 𝜂𝜂𝑆𝑆𝐷𝐷 𝑁𝑁 𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉�  
     
0.50 2.0 0.307 182 0.83 
0.45 2.0 0.293 200 0.85 
0.40 2.0 0.280 219 0.86 
0.35 2.0 0.269 237 0.86 
0.30 2.0 0.258 258 0.85 
Note. 𝜃𝜃  is the equivalence margin; 𝛾𝛾𝑎𝑎𝑎𝑎  is the response rate of the initial treatment 𝑎𝑎𝑎𝑎  that 
corresponds to both AIs 𝑑𝑑4 and 𝑑𝑑3 (𝛾𝛾𝑎𝑎 is the response rate to the other initial treatment 𝑎𝑎, and 
is set to be equal to 𝛾𝛾𝑎𝑎𝑎𝑎 while simulating the equivalence trials); 𝜂𝜂𝑆𝑆𝐷𝐷 is the standardized effect 
size. The required sample size 𝑁𝑁 is calculated based on equation (14) and the estimated power 
(𝑝𝑝𝑐𝑐𝑤𝑤𝑒𝑒𝑉𝑉� ) is based on 1000 Monte Carlo simulations.  
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Table 6. Results of the equivalence test when there is no effect involving the distinct-path AIs 
{𝑑𝑑1,𝑑𝑑3} 
( 𝛾𝛾𝑎𝑎 , 𝛾𝛾𝑎𝑎𝑎𝑎 ) 𝜃𝜃 𝜂𝜂𝐷𝐷𝐷𝐷 𝑁𝑁 𝑇𝑇𝑇𝑇𝑝𝑝𝑒𝑒 − 𝐼𝐼 𝑒𝑒𝑉𝑉𝑉𝑉𝑐𝑐𝑉𝑉 𝑉𝑉𝑎𝑎𝑟𝑟𝑒𝑒�  
 2.0  244 0.038 
 2.0  500 0.037 
(0.45, 0.45) 2.0 0.265 1000 0.033 
 2.0  2000 0.043 
 2.0  5000 0.043 
 
Note. 𝜃𝜃 is the equivalence margin; 𝛾𝛾𝑎𝑎 and 𝛾𝛾𝑎𝑎𝑎𝑎 are the response rates of initial treatments 𝑎𝑎 
and 𝑎𝑎𝑎𝑎, corresponding to the AIs 𝑑𝑑1 and 𝑑𝑑3 respectively; 𝜂𝜂𝐷𝐷𝐷𝐷 is the standardized effect size. 
The required sample size 𝑁𝑁 = 244 is calculated based on equation (13) and the estimated Type-
I error rate is based on 1000 Monte Carlo simulations. Other values of N, 500-5000, are provided 
to check that the Type-I error rate is controlled at 5% when there is no effect. Here the 𝛿𝛿𝐷𝐷𝐷𝐷 is 
fixed at 2 ensuring there is no effect with respect to the equivalence margin 𝜃𝜃 = 2. 
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Table 7: Results of the equivalence test when there is no effect involving the shared-path AIs 
{𝑑𝑑4,𝑑𝑑3} 
   
𝛾𝛾𝑎𝑎𝑎𝑎 𝜃𝜃 𝜂𝜂𝑆𝑆𝐷𝐷 𝑁𝑁 𝑇𝑇𝑇𝑇𝑝𝑝𝑒𝑒 − 𝐼𝐼 𝑒𝑒𝑉𝑉𝑉𝑉𝑐𝑐𝑉𝑉 𝑉𝑉𝑎𝑎𝑟𝑟𝑒𝑒�  
     
 2.0  175 0.066 
 2.0  500 0.039 
0.45 2.0 0.313 1000 0.041 
 2.0  2000 0.055 
 2.0  5000 0.051 
Note. 𝜃𝜃  is the equivalence margin; 𝛾𝛾𝑎𝑎𝑎𝑎  is the response rate of the initial treatment 𝑎𝑎𝑎𝑎  that 
corresponds to both AIs 𝑑𝑑4 and 𝑑𝑑3 (𝛾𝛾𝑎𝑎 is the response rate to the other initial treatment 𝑎𝑎, and 
is set to be equal to 𝛾𝛾𝑎𝑎𝑎𝑎 while simulating the equivalence trials); 𝜂𝜂𝑆𝑆𝐷𝐷 is the standardized effect 
size. The required sample size 𝑁𝑁 = 175 is calculated based on equation (14) and the estimated 
Type-I error rate is based on 1000 Monte Carlo simulations. Other values of N, 500-5000, are 
provided to check whether the Type-I error rate is controlled at 5% when there is no effect. Here 
the 𝛿𝛿𝑆𝑆𝐷𝐷 is fixed at 1.99 ensuring there is no effect with respect to the equivalence margin 𝜃𝜃 = 2. 
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Figure 3: Power Curves for non-inferiority and equivalence tests for comparing distinct-path and 
shared-path adaptive interventions. For a given  𝑁𝑁 (100, 200, 300 or 500) and a standardized 
effect size (for distinct-path: (𝜂𝜂𝐷𝐷𝐷𝐷(θ) − 𝜂𝜂𝐷𝐷𝐷𝐷(δ) and for shared-path: (𝜂𝜂𝑆𝑆𝐷𝐷(θ) − 𝜂𝜂𝑆𝑆𝐷𝐷(δ)), the 
power is based on 1000 Monte Carlo simulations. 
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A  Appendix 
A.1  Derivation of Mean of an Adaptive Intervention 
 We will use 𝑌𝑌 as the primary outcome instead of 𝑌𝑌𝑇𝑇1𝑇𝑇2 to refer an individual's primary 
outcome with respect to the entire study. Note that the response indicator 𝑅𝑅 = 𝐼𝐼(𝑇𝑇1 = 𝑇𝑇2); and, 
∑𝑁𝑁𝑖𝑖=1 𝑊𝑊𝑖𝑖
𝑑𝑑1 = 𝑁𝑁, when empirical randomization probabilities are exactly same as the 
corresponding theoretical probabilities. From (2), using the independence among the different 
patients in the study, we have  
 𝜇𝜇𝑑𝑑1 = 𝐸𝐸(𝑌𝑌𝑑𝑑1) = 𝐸𝐸[𝑊𝑊𝑑𝑑1𝑌𝑌] = 𝐸𝐸 �𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅 𝑌𝑌|𝑇𝑇1,𝑇𝑇2�� 
 = 𝑃𝑃(𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎)𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎}𝜋𝜋𝑎𝑎 𝑌𝑌|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎� 
 +𝑃𝑃(𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣)𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑣𝑣}𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣 𝑌𝑌|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣� + 0, 
        (𝑟𝑟ℎ𝑒𝑒  𝑙𝑙𝑎𝑎𝑣𝑣𝑟𝑟  𝑟𝑟𝑒𝑒𝑉𝑉𝑚𝑚:  𝑖𝑖𝑖𝑖   𝑇𝑇1 =
𝑎𝑎𝑎𝑎   𝑟𝑟ℎ𝑒𝑒𝑎𝑎  𝑖𝑖𝑟𝑟  𝑎𝑎𝑐𝑐𝑎𝑎𝑟𝑟𝑉𝑉𝑖𝑖𝑐𝑐𝑐𝑐𝑟𝑟𝑒𝑒𝑣𝑣  0  𝑑𝑑𝑐𝑐𝑒𝑒  𝑟𝑟ℎ𝑒𝑒  𝑖𝑖𝑎𝑎𝑑𝑑𝑖𝑖𝑎𝑎𝑎𝑎𝑟𝑟𝑐𝑐𝑉𝑉  𝑖𝑖𝑐𝑐𝑎𝑎𝑎𝑎𝑟𝑟𝑖𝑖𝑐𝑐𝑎𝑎)  
 = 𝑃𝑃(𝑇𝑇1 = 𝑎𝑎)𝑃𝑃(𝑇𝑇2 = 𝑎𝑎|𝑇𝑇1 = 𝑎𝑎)𝐸𝐸 � 1𝜋𝜋𝑎𝑎 𝑌𝑌|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎� 
 +𝑃𝑃(𝑇𝑇1 = 𝑎𝑎)𝑃𝑃(𝑇𝑇2 = 𝑣𝑣|𝑇𝑇1 = 𝑎𝑎)𝐸𝐸 � 1𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣 𝑌𝑌|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣� 
 = 𝜋𝜋𝑎𝑎𝛾𝛾𝑎𝑎 1𝜋𝜋𝑎𝑎 𝜇𝜇𝑎𝑎,𝑎𝑎 + 𝜋𝜋𝑎𝑎(1 − 𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎,𝑣𝑣 1𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜇𝜇𝑎𝑎,𝑣𝑣 
 = 𝛾𝛾𝑎𝑎𝜇𝜇𝑎𝑎,𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑣𝑣. (15) 
 Similarly, 𝜇𝜇𝑑𝑑2 = 𝛾𝛾𝑎𝑎𝜇𝜇𝑎𝑎,𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑚𝑚 ; 𝜇𝜇𝑑𝑑3 = 𝛾𝛾𝑎𝑎,𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣  and 𝜇𝜇𝑑𝑑4 =
𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚. 
 
A.2  Derivation of Variance of the Mean of an Adaptive Intervention 
62 
 
 𝑉𝑉𝑎𝑎𝑉𝑉(?̂?𝜇𝑑𝑑1) = 1𝑁𝑁 𝑉𝑉𝑎𝑎𝑉𝑉[𝑊𝑊𝑑𝑑1𝑌𝑌],     (𝑐𝑐𝑣𝑣𝑖𝑖𝑎𝑎𝑢𝑢  𝑖𝑖𝑎𝑎𝑑𝑑𝑒𝑒𝑝𝑝𝑒𝑒𝑎𝑎𝑑𝑑𝑒𝑒𝑎𝑎𝑟𝑟  𝑐𝑐𝑐𝑐𝑣𝑣𝑒𝑒𝑉𝑉𝑣𝑣𝑎𝑎𝑟𝑟𝑖𝑖𝑐𝑐𝑎𝑎𝑣𝑣)  
 = 1
𝑁𝑁
�𝑉𝑉𝑎𝑎𝑉𝑉 �
𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}
𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅 𝑌𝑌�� 
 = 1
𝑁𝑁
�𝐸𝐸 �
𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}(𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅)2 𝑌𝑌2� − 𝐸𝐸2 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅 𝑌𝑌��. (16) 
 Note that, from (15), we have the expected mean of the AI 𝑑𝑑1,  
 𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}
𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅 𝑌𝑌� = 𝛾𝛾𝐴𝐴𝜇𝜇𝑎𝑎,𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑣𝑣. (17) 
 Now, the first part of (16),  
 𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅}(𝜋𝜋𝑎𝑎×𝜋𝜋𝑎𝑎,𝑣𝑣1−𝑅𝑅)2 𝑌𝑌2� 
 = 𝑃𝑃(𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎)𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑎𝑎}𝜋𝜋𝑎𝑎2 𝑌𝑌2|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎� 
 +𝑃𝑃(𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣)𝐸𝐸 �𝐼𝐼{𝑇𝑇1=𝑎𝑎,𝑇𝑇2=𝑣𝑣}𝜋𝜋𝑎𝑎2×𝜋𝜋𝑎𝑎,𝑣𝑣2 𝑌𝑌2|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣� + 0, 
        (𝑟𝑟ℎ𝑒𝑒  𝑙𝑙𝑎𝑎𝑣𝑣𝑟𝑟  𝑟𝑟𝑒𝑒𝑉𝑉𝑚𝑚:  𝑖𝑖𝑖𝑖   𝑇𝑇1 =
𝑎𝑎𝑎𝑎   𝑟𝑟ℎ𝑒𝑒𝑎𝑎  𝑖𝑖𝑟𝑟  𝑎𝑎𝑐𝑐𝑎𝑎𝑟𝑟𝑉𝑉𝑖𝑖𝑐𝑐𝑐𝑐𝑟𝑟𝑒𝑒𝑣𝑣  0  𝑑𝑑𝑐𝑐𝑒𝑒  𝑟𝑟ℎ𝑒𝑒  𝑖𝑖𝑎𝑎𝑑𝑑𝑖𝑖𝑎𝑎𝑎𝑎𝑟𝑟𝑐𝑐𝑉𝑉  𝑖𝑖𝑐𝑐𝑎𝑎𝑎𝑎𝑟𝑟𝑖𝑖𝑐𝑐𝑎𝑎)  
 = 𝑃𝑃(𝑇𝑇1 = 𝑎𝑎)𝑃𝑃(𝑇𝑇2 = 𝑎𝑎|𝑇𝑇1 = 𝑎𝑎)𝐸𝐸 � 1𝜋𝜋𝑎𝑎2 𝑌𝑌2|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑎𝑎� 
 +𝑃𝑃(𝑇𝑇1 = 𝑎𝑎)𝑃𝑃(𝑇𝑇2 = 𝑣𝑣|𝑇𝑇1 = 𝑎𝑎)𝐸𝐸 � 1𝜋𝜋𝑎𝑎2×𝜋𝜋𝑎𝑎,𝑣𝑣2 𝑌𝑌2|𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣� 
 = 𝜋𝜋𝑎𝑎𝛾𝛾𝑎𝑎 1𝜋𝜋𝑎𝑎2 (𝜎𝜎2 + 𝜇𝜇𝑎𝑎,𝑎𝑎2 ) + 𝜋𝜋𝑎𝑎(1 − 𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎,𝑣𝑣 1𝜋𝜋𝑎𝑎2𝜋𝜋𝑎𝑎,𝑣𝑣2 (𝜎𝜎2 + 𝜇𝜇𝑎𝑎,𝑣𝑣2 ) 
 = 𝛾𝛾𝑎𝑎
𝜋𝜋𝑎𝑎
(𝜎𝜎2 + 𝜇𝜇𝑎𝑎,𝑎𝑎2 ) + (1−𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 (𝜎𝜎2 + 𝜇𝜇𝑎𝑎,𝑣𝑣2 ) 
 = 1−𝛾𝛾𝑎𝑎+𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣
𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜎𝜎2 + 𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎 𝜇𝜇𝑎𝑎,𝑎𝑎2 + (1−𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜇𝜇𝑎𝑎,𝑣𝑣2 . (18) 
 Finally, from (16), using (17) and (18), we have  
 𝑉𝑉𝑎𝑎𝑉𝑉(?̂?𝜇𝑑𝑑1) 
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 = 1
𝑁𝑁
�
1−𝛾𝛾𝑎𝑎+𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣
𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜎𝜎2 + 𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎 𝜇𝜇𝑎𝑎,𝑎𝑎2 + (1−𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜇𝜇𝑎𝑎,𝑣𝑣2 − (𝛾𝛾𝑎𝑎𝜇𝜇𝑎𝑎,𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑣𝑣)2� 
 = 1
𝑁𝑁
{1−𝛾𝛾𝑎𝑎+𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣
𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜎𝜎2 + 𝛾𝛾𝑎𝑎(1−𝛾𝛾𝑎𝑎𝜋𝜋𝑎𝑎)𝜋𝜋𝑎𝑎 𝜇𝜇𝑎𝑎,𝑎𝑎2 + (1−𝛾𝛾𝑎𝑎)(1−(1−𝛾𝛾𝑎𝑎)𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣)𝜋𝜋𝑎𝑎𝜋𝜋𝑎𝑎,𝑣𝑣 𝜇𝜇𝑎𝑎,𝑣𝑣2  
     −2𝛾𝛾𝑎𝑎(1 − 𝛾𝛾𝑎𝑎)𝜇𝜇𝑎𝑎,𝑎𝑎𝜇𝜇𝑎𝑎,𝑣𝑣} (19) 
 
A.3  Non-Inferiority Test: Sample Size for Comparing Distinct-Path AIs 
 Here, we calculate the sample size formula to corresponding to a non-inferiority test to 
decide whether the AI 𝑑𝑑1 is non-inferior in efficacy to AI 𝑑𝑑3. We can write the power of the test 
as (Friedman et al., 2015) 
𝑃𝑃𝐻𝐻1[   𝑉𝑉𝑒𝑒𝑗𝑗𝑒𝑒𝑎𝑎𝑟𝑟   𝐻𝐻0] = 𝑃𝑃𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1=𝛿𝛿
⎣
⎢
⎢
⎡𝑌𝑌𝑑𝑑3 − 𝑌𝑌𝑑𝑑1 − 𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
<  −𝑧𝑧𝛼𝛼
⎦
⎥
⎥
⎤
 
 
 = 𝑃𝑃𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1=𝛿𝛿 �𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1−𝛿𝛿�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 − 𝜃𝜃−𝛿𝛿�𝜈𝜈𝑑𝑑1𝑑𝑑3𝐷𝐷𝐷𝐷 < −𝑧𝑧𝛼𝛼� 
 = 𝑃𝑃 �𝑍𝑍 < −𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� ,   𝑣𝑣𝑖𝑖𝑎𝑎𝑎𝑎𝑒𝑒,   𝑍𝑍 = 𝑌𝑌𝑑𝑑3−𝑌𝑌𝑑𝑑1−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
→ 𝑁𝑁(0,1) 
        𝑐𝑐𝑎𝑎𝑑𝑑𝑒𝑒𝑉𝑉   𝐻𝐻1 
 = Φ�−𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
�, 
  𝑐𝑐𝑉𝑉,   1 − 𝛽𝛽 = 1 −Φ�𝑧𝑧𝛼𝛼 − 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
�, 
 Φ�𝑧𝑧𝛼𝛼 −
𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� = 𝛽𝛽 = Φ(𝑧𝑧1−𝛽𝛽) 
64 
 
 𝑧𝑧𝛼𝛼 −
𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
= 𝑧𝑧1−𝛽𝛽 = −𝑧𝑧𝛽𝛽 
 𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽 = 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
= 𝜃𝜃−𝛿𝛿
�(𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 )/𝑁𝑁 
 (𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2 = 𝑁𝑁(𝜃𝜃−𝛿𝛿)2(𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 ) 
 𝑁𝑁 = (𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽)2 (𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 )(𝜃𝜃−𝛿𝛿)2 . 
Note that 𝜃𝜃 = 𝛿𝛿 means 𝐻𝐻0 is true, then 𝑁𝑁 =∞. In all other cases, the above formula will give 
reasonable sample sizes. If 0 < 𝛿𝛿 < 𝜃𝜃, 𝑁𝑁 will be high; if 𝛿𝛿 < 0, 𝑁𝑁 will be relatively small. 
 
A.4  Non-Inferiority Test: Variance Formula for Comparing Shared-Path AIs 
 The variance of 𝑌𝑌𝑑𝑑3 − 𝑌𝑌𝑑𝑑4 is given by  
 𝑉𝑉(?̂?𝜇𝑑𝑑3 − ?̂?𝜇𝑑𝑑4) = 𝑉𝑉(?̂?𝜇𝑑𝑑3) + 𝑉𝑉(?̂?𝜇𝑑𝑑4) − 2𝐶𝐶𝑐𝑐𝑣𝑣(?̂?𝜇𝑑𝑑3 , ?̂?𝜇𝑑𝑑4). (20) 
 Now,  
 𝐶𝐶𝑐𝑐𝑣𝑣(?̂?𝜇𝑑𝑑3 , ?̂?𝜇𝑑𝑑4) = 𝐶𝐶𝑐𝑐𝑣𝑣(1𝑁𝑁∑𝑁𝑁𝑖𝑖=1 𝑊𝑊𝑖𝑖𝑑𝑑3𝑌𝑌𝑖𝑖 , 1𝑁𝑁 ∑𝑁𝑁𝑖𝑖=1 𝑊𝑊𝑖𝑖𝑑𝑑4𝑌𝑌𝑖𝑖) 
 = 𝐶𝐶𝑐𝑐𝑣𝑣(1
𝑁𝑁
∑𝑁𝑁𝑖𝑖=1
𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖, 1𝑁𝑁 ∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑚𝑚1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖) 
 = 1
𝑁𝑁2
[𝐸𝐸(∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖 × ∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑚𝑚1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖)] 
 −𝐸𝐸(1
𝑁𝑁
∑𝑁𝑁𝑖𝑖=1
𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖)𝐸𝐸(1𝑁𝑁∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑚𝑚1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖).     (21) 
 We have  
 𝐸𝐸(1
𝑁𝑁
∑𝑁𝑁𝑖𝑖=1
𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖) = 𝛾𝛾𝐴𝐴𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝐴𝐴)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣, (22) 
 𝐸𝐸(1
𝑁𝑁
∑𝑁𝑁𝑖𝑖=1
𝐼𝐼{𝑇𝑇1𝑖𝑖=ac,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑚𝑚1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖) = 𝛾𝛾𝐴𝐴𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝐴𝐴)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚. (23) 
65 
 
 Now,  
 𝐸𝐸(∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖 × ∑𝑁𝑁𝑖𝑖=1 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑚𝑚1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖) 
 = ∑𝑁𝑁𝑖𝑖=1 ∑𝑁𝑁𝑗𝑗=1 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖 × 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎𝑅𝑅𝑗𝑗𝑚𝑚1−𝑅𝑅𝑗𝑗}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑗𝑗 𝑌𝑌𝑗𝑗) 
 = ∑𝑁𝑁𝑖𝑖=1 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖 × 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖) 
 +∑𝑖𝑖≠𝑗𝑗 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖 × 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎𝑅𝑅𝑗𝑗𝑚𝑚1−𝑅𝑅𝑗𝑗}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎)1−𝑅𝑅𝑗𝑗 𝑌𝑌𝑗𝑗) 
 = 𝐴𝐴(𝑖𝑖=𝑗𝑗) + 𝐴𝐴(𝑖𝑖≠𝑗𝑗), (24) 
 where,  
 𝐴𝐴(𝑖𝑖=𝑗𝑗) = ∑𝑁𝑁𝑖𝑖=1 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖 × 𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖) 
 = 1
𝜋𝜋𝑎𝑎𝑎𝑎
2 ∑
𝑁𝑁
𝑖𝑖=1 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎}𝑌𝑌𝑖𝑖2) 
 = 1
𝜋𝜋𝑎𝑎𝑎𝑎
2 ∑
𝑁𝑁
𝑖𝑖=1 [𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎}𝑌𝑌𝑖𝑖2|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎)𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 =
𝑎𝑎𝑎𝑎) + 0] 
 = 1
𝜋𝜋𝑎𝑎𝑎𝑎
2 ∑
𝑁𝑁
𝑖𝑖=1 [𝐸𝐸(𝑌𝑌𝑖𝑖2|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎)𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎)𝑃𝑃(𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎)] 
 = 1
𝜋𝜋𝑎𝑎𝑎𝑎
2 ∑
𝑁𝑁
𝑖𝑖=1 (𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 )𝜋𝜋𝑎𝑎𝑎𝑎𝛾𝛾𝑎𝑎𝑎𝑎 
 = 𝑁𝑁
𝜋𝜋𝑎𝑎𝑎𝑎
𝛾𝛾𝑎𝑎𝑎𝑎(𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 ), (25) 
 and,  
 𝐴𝐴(𝑖𝑖≠𝑗𝑗) 
 = ∑𝑖𝑖≠𝑗𝑗 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 𝑌𝑌𝑖𝑖 ⋅ 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎𝑅𝑅𝑗𝑗𝑚𝑚1−𝑅𝑅𝑗𝑗}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑗𝑗 𝑌𝑌𝑗𝑗) 
 = ∑𝑖𝑖≠𝑗𝑗 [∑𝑇𝑇2𝑖𝑖,𝑇𝑇2𝑗𝑗 𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎𝑅𝑅𝑖𝑖𝑣𝑣1−𝑅𝑅𝑖𝑖}𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣1−𝑅𝑅𝑖𝑖 ⋅ 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎𝑅𝑅𝑗𝑗𝑚𝑚1−𝑅𝑅𝑗𝑗}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣)1−𝑅𝑅𝑗𝑗 𝑌𝑌𝑖𝑖𝑌𝑌𝑗𝑗| 
66 
 
     𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗) × 𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 ,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗) + 0] 
 = ∑𝑖𝑖≠𝑗𝑗 [𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 ⋅ 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖𝑌𝑌𝑗𝑗|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇1𝑗𝑗 =
𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑎𝑎𝑎𝑎) 
     × 𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑎𝑎𝑎𝑎) 
 +𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑎𝑎𝑎𝑎}
𝜋𝜋𝑎𝑎𝑎𝑎
⋅
𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑚𝑚}
𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣) 𝑌𝑌𝑖𝑖𝑌𝑌𝑗𝑗|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑚𝑚) 
     × 𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑚𝑚) 
 +𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑣𝑣}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣 ⋅ 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑎𝑎𝑎𝑎}𝜋𝜋𝑎𝑎𝑎𝑎 𝑌𝑌𝑖𝑖𝑌𝑌𝑗𝑗|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑣𝑣,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑎𝑎𝑎𝑎) 
     × 𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑣𝑣,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑎𝑎𝑎𝑎) 
 +𝐸𝐸(𝐼𝐼{𝑇𝑇1𝑖𝑖=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖=𝑣𝑣}
𝜋𝜋𝑎𝑎𝑎𝑎×𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣 ⋅ 𝐼𝐼{𝑇𝑇1𝑗𝑗=𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗=𝑚𝑚}𝜋𝜋𝑎𝑎𝑎𝑎×(1−𝜋𝜋𝑎𝑎𝑎𝑎,𝑣𝑣) 𝑌𝑌𝑖𝑖𝑌𝑌𝑗𝑗|𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑣𝑣,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑚𝑚) 
     × 𝑃𝑃(𝑇𝑇1𝑖𝑖 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑖𝑖 = 𝑣𝑣,𝑇𝑇1𝑗𝑗 = 𝑎𝑎𝑎𝑎,𝑇𝑇2𝑗𝑗 = 𝑚𝑚)] 
 = 𝑁𝑁(𝑁𝑁 − 1)[𝛾𝛾𝑎𝑎𝑎𝑎2 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 + 𝛾𝛾𝑎𝑎𝑎𝑎(1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚 + 𝛾𝛾𝑎𝑎𝑎𝑎(1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣 +(1 − 𝛾𝛾𝑎𝑎𝑎𝑎)2𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚] 
 = 𝑁𝑁(𝑁𝑁 − 1) × (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣) × (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚). (26) 
 Using, (21) (22), (23), (24), (25) and (26), we have  
 𝐶𝐶𝑐𝑐𝑣𝑣(?̂?𝜇𝑑𝑑3 , ?̂?𝜇𝑑𝑑4) 
 = 1
𝑁𝑁2
[ 𝑁𝑁
𝜋𝜋𝑎𝑎𝑎𝑎
𝛾𝛾𝑎𝑎𝑎𝑎(𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 ) + 𝑁𝑁(𝑁𝑁 − 1) ⋅ (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣) ⋅(𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚)] 
     −(𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣) ⋅ (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚) 
 = 1
𝑁𝑁
[𝛾𝛾𝑎𝑎𝑎𝑎
𝜋𝜋𝑎𝑎𝑎𝑎
(𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 ) − (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣) ⋅ (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 −
𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚)]. (27) 
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Hence, using ((20)) and ((27)),  
 𝑉𝑉(?̂?𝜇𝑑𝑑3 − ?̂?𝜇𝑑𝑑4) = 𝑉𝑉(?̂?𝜇𝑑𝑑3) + 𝑉𝑉(?̂?𝜇𝑑𝑑4) 
     − 2
𝑁𝑁
[𝛾𝛾𝑎𝑎𝑎𝑎
𝜋𝜋𝑎𝑎𝑎𝑎
(𝜎𝜎2 + 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎2 ) − (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 − 𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑣𝑣) ⋅ (𝛾𝛾𝑎𝑎𝑎𝑎𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 + (1 −
𝛾𝛾𝑎𝑎𝑎𝑎)𝜇𝜇𝑎𝑎𝑎𝑎,𝑚𝑚)]. (28) 
 
A.5  Equivalence Test: Power of Comparing Distinct-Path AIs 
Here we provide the formula, which can be used to obtain the sample size in an equivalence 
test that decides whether the AI 𝑑𝑑1 is equivalent in efficacy to the AI 𝑑𝑑3. We can write the power 
of the test as (Friedman et al., 2015) 
 𝑃𝑃𝐻𝐻1 �
𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1−𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
< −𝑧𝑧𝛼𝛼    𝑎𝑎𝑎𝑎𝑑𝑑   𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1+𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
> 𝑧𝑧𝛼𝛼�, 
 where 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1 ∈ (−𝜃𝜃, 𝜃𝜃) under 𝐻𝐻1. When 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1 = 𝛿𝛿 ∈ (−𝜃𝜃,𝜃𝜃), then the power  
 𝑃𝑃𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1=𝛿𝛿 �
𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1−𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
< −𝑧𝑧𝛼𝛼   𝑎𝑎𝑎𝑎𝑑𝑑   𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1+𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
> 𝑧𝑧𝛼𝛼� 
 = 𝑃𝑃𝜇𝜇𝑑𝑑3−𝜇𝜇𝑑𝑑1=𝛿𝛿 �𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1−𝛿𝛿�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 − 𝜃𝜃−𝛿𝛿�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 < −𝑧𝑧𝛼𝛼   𝑎𝑎𝑎𝑎𝑑𝑑   𝑌𝑌�𝑑𝑑3−𝑌𝑌�𝑑𝑑1−𝛿𝛿�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 + 𝜃𝜃+𝛿𝛿�𝜈𝜈𝑑𝑑3𝑑𝑑1𝐷𝐷𝐷𝐷 >
−𝑧𝑧𝛼𝛼� 
 = 𝑃𝑃 �𝑍𝑍 < −𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
   𝑎𝑎𝑎𝑎𝑑𝑑   𝑍𝑍 > 𝑧𝑧𝛼𝛼 − 𝜃𝜃+𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� 
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 = 𝑃𝑃 �𝑧𝑧𝛼𝛼 − 𝜃𝜃+𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
< 𝑍𝑍 < −𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� 
 = Φ�−𝑧𝑧𝛼𝛼 + 𝜃𝜃−𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� − Φ�𝑧𝑧𝛼𝛼 −
𝜃𝜃+𝛿𝛿
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
�, (29) 
 which is equal to 1 − 𝛽𝛽. In a special case, when 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1 = 𝛿𝛿 = 0, (29) becomes  
 1 − 𝛽𝛽 = Φ�−𝑧𝑧𝛼𝛼 + 𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� − Φ�𝑧𝑧𝛼𝛼 −
𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� = 1 − 2Φ�𝑧𝑧𝛼𝛼 − 𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� 
 ⇒ Φ�𝑧𝑧𝛼𝛼 −
𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
� = 𝛽𝛽
2
= Φ�𝑧𝑧
1−
𝛽𝛽
2
� 
 ⇒ 𝑧𝑧𝛼𝛼 −
𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
= 𝑧𝑧
1−
𝛽𝛽
2
= −𝑧𝑧𝛽𝛽
2
 
 ⇒ 𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽
2
= 𝜃𝜃
�𝜈𝜈𝑑𝑑3𝑑𝑑1
𝐷𝐷𝐷𝐷
= 𝜃𝜃
�(𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 )/𝑁𝑁 
 ⇒ �𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽
2
�
2 = 𝑁𝑁𝜃𝜃2(𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 ) 
 ⇒ 𝑁𝑁 = �𝑧𝑧𝛼𝛼 + 𝑧𝑧𝛽𝛽
2
�
2 (𝜎𝜎𝑑𝑑32 +𝜎𝜎𝑑𝑑12 )
𝜃𝜃2
. 
 
A.6  Data Generation for a SMART 
 
 The data generation process for a SMART is complex. Here we outline an algorithm that 
generates datasets from a SMART (as depicted in Figure 1) to conduct simulation studies. The 
algorithm is as follows.   
1. Set the values of: 𝑉𝑉𝑎𝑎𝑉𝑉(𝑌𝑌) = 𝜎𝜎2, 𝛾𝛾𝑎𝑎𝑎𝑎, 𝛾𝛾𝑎𝑎𝑎𝑎, 𝛼𝛼, 𝛽𝛽. 
 
69 
 
2. Set the mean and variance of a latent variable 𝐿𝐿 for the patient with treatment 𝑎𝑎 at first 
stage as 𝜇𝜇𝐿𝐿𝑎𝑎 ,𝜎𝜎𝐿𝐿2, respectively. The latent variable can be viewed as a proximal outcome, 
which determines responder/non-responder status after the first stage. 
 
3. Define the cut-off value 𝜂𝜂 as that value of the latent variable 𝐿𝐿 above which a patient is 
considered a responder. So  
 𝜂𝜂 = 𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜎𝜎𝐿𝐿 × Φ−1(1 − 𝛾𝛾𝑎𝑎), 
 where Φ is the cumulative distribution function of the standard normal distribution. 
 
4. The cut-off 𝜂𝜂 should be fixed for a SMART irrespective of the choice of initial treatment 
(𝑎𝑎 or 𝑎𝑎𝑎𝑎). So we define  
 𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 = 𝜂𝜂 − 𝜎𝜎𝐿𝐿 × Φ−1(1 − 𝛾𝛾𝑎𝑎𝑎𝑎). 
 
5. Define the truncated normal means of the non-responders (NR) who obtained the first-
stage treatment 𝑎𝑎 or 𝑎𝑎𝑎𝑎 as  
𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅 = 𝜇𝜇𝐿𝐿𝑎𝑎 − 𝜎𝜎𝐿𝐿 × 𝜙𝜙(𝑐𝑐∗)Φ(𝑐𝑐∗) ,   𝑤𝑤ℎ𝑒𝑒𝑉𝑉𝑒𝑒   𝑐𝑐∗ = 𝜂𝜂 − 𝜇𝜇𝐿𝐿𝑎𝑎𝜎𝜎𝐿𝐿 ,   𝑎𝑎𝑎𝑎𝑑𝑑    
       𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎.𝑁𝑁𝑅𝑅 = 𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 − 𝜎𝜎𝐿𝐿 × 𝜙𝜙(𝑤𝑤∗)Φ(𝑤𝑤∗) ,   𝑤𝑤ℎ𝑒𝑒𝑉𝑉𝑒𝑒   𝑤𝑤∗ = 𝜂𝜂 − 𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎𝜎𝜎𝐿𝐿 ,   𝑉𝑉𝑒𝑒𝑣𝑣𝑝𝑝𝑒𝑒𝑎𝑎𝑟𝑟𝑖𝑖𝑣𝑣𝑒𝑒𝑙𝑙𝑇𝑇.  
Here, 𝜙𝜙 is the probability density function of the standard normal distribution.  
6. The AI means corresponding to the AIs 𝑑𝑑1: (𝑎𝑎, 𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅) , 𝑑𝑑2: (𝑎𝑎, 𝑎𝑎𝑅𝑅𝑚𝑚1−𝑅𝑅) , 
𝑑𝑑3: (𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝑅𝑅𝑣𝑣1−𝑅𝑅) and 𝑑𝑑4: (𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝑅𝑅𝑚𝑚1−𝑅𝑅) can be defined as (see equation (15)) 
 𝜇𝜇𝑑𝑑1 = (𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎) × 𝛾𝛾𝑎𝑎 + (𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜉𝜉2𝑎𝑎,𝑣𝑣𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅) × (1 − 𝛾𝛾𝑎𝑎), 
 𝜇𝜇𝑑𝑑2 = (𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎) × 𝛾𝛾𝑎𝑎 + (𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜉𝜉2𝑎𝑎,𝑚𝑚𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅) × (1 − 𝛾𝛾𝑎𝑎), 
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 𝜇𝜇𝑑𝑑3 = (𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎) × 𝛾𝛾𝑎𝑎𝑎𝑎 + (𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 + 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑣𝑣𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎.𝑁𝑁𝑅𝑅) × (1 − 𝛾𝛾𝑎𝑎𝑎𝑎), 
 𝜇𝜇𝑑𝑑4 = (𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎) × 𝛾𝛾𝑎𝑎𝑎𝑎 + (𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 + 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑚𝑚𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎.𝑁𝑁𝑅𝑅) × (1 − 𝛾𝛾𝑎𝑎𝑎𝑎), 
respectively. Here, �𝜁𝜁0, 𝜁𝜁1𝑎𝑎 , 𝜁𝜁1𝑎𝑎𝑎𝑎 , 𝜉𝜉0, 𝜉𝜉1𝑎𝑎, 𝜉𝜉1𝑎𝑎𝑎𝑎 , 𝜉𝜉2𝑎𝑎,𝑣𝑣, 𝜉𝜉2𝑎𝑎,𝑚𝑚, 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑣𝑣, 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑚𝑚�  are (fixed) 
parameters to be supplied by the user. Note that 𝜇𝜇𝑎𝑎,𝑎𝑎 = 𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎  shows the 
dependency of the mean parameter 𝜇𝜇𝑎𝑎,𝑎𝑎 on the mean of the latent variable (𝜇𝜇𝐿𝐿𝑎𝑎) using 
the parameters {𝜁𝜁0, 𝜁𝜁1𝑎𝑎}  (see equation (15)); the 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 =  𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎  shows the 
dependency of the mean parameter 𝜇𝜇𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎 on the mean of the latent variable (𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎) using 
the parameters {𝜁𝜁0, 𝜁𝜁1𝑎𝑎𝑎𝑎}. The 𝜇𝜇𝑎𝑎,𝑣𝑣 = 𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜉𝜉2𝑎𝑎,𝑣𝑣𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅  shows the dependency 
of the mean parameter 𝜇𝜇𝑎𝑎,𝑣𝑣 on the mean of the latent variables (𝜇𝜇𝐿𝐿𝑎𝑎  𝑎𝑎𝑎𝑎𝑑𝑑 𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅) using 
the parameters {𝜉𝜉0, 𝜉𝜉1𝑎𝑎, 𝜉𝜉2𝑎𝑎,𝑣𝑣}. Similarly other parameters {𝜉𝜉1𝑎𝑎𝑎𝑎 , 𝜉𝜉2𝑎𝑎,𝑚𝑚, 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑣𝑣, 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑚𝑚} can 
be interpreted.  
 
7. Define the effect size between the two distinct-path AIs 𝑑𝑑1 and 𝑑𝑑3 as 𝛿𝛿𝐷𝐷𝐷𝐷 = 𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑1. 
Similarly, define the effect size between the two shared-path AIs 𝑑𝑑3 and 𝑑𝑑4 as 𝛿𝛿𝑆𝑆𝐷𝐷 =
𝜇𝜇𝑑𝑑3 − 𝜇𝜇𝑑𝑑4. 
 
8. Fix the value 𝑁𝑁 for power curve, otherwise calculate the required minimum value of 𝑁𝑁. 
 
9. Generate 𝑁𝑁𝑎𝑎 = 𝑎𝑎𝑒𝑒𝑖𝑖𝑙𝑙𝑖𝑖𝑎𝑎𝑢𝑢(𝑁𝑁/2)  random draws from 𝑁𝑁(𝜇𝜇𝐿𝐿𝑎𝑎 ,𝜎𝜎𝐿𝐿2)  and generate 𝑁𝑁𝑎𝑎𝑎𝑎 =
𝑁𝑁 − 𝑁𝑁𝑎𝑎 random draws from 𝑁𝑁(𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 ,𝜎𝜎𝐿𝐿2). 
 
10. Finally generate 𝑁𝑁𝑇𝑇1,𝑇𝑇2 number of primary outcomes 𝑌𝑌 from 𝑁𝑁(𝜇𝜇𝑇𝑇1,𝑇𝑇2 ,𝜎𝜎2), where  
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 𝜇𝜇𝑇𝑇1,𝑇𝑇2 =
⎝
⎜
⎜
⎜
⎜
⎛
𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 if 𝑇𝑇1 = 𝑇𝑇2 = 𝑎𝑎
𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜉𝜉2𝑎𝑎,𝑣𝑣𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅 if 𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑣𝑣
𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎 + 𝜉𝜉2𝑎𝑎,𝑚𝑚𝜇𝜇𝐿𝐿𝑎𝑎.𝑁𝑁𝑅𝑅 if 𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 = 𝑚𝑚
𝜁𝜁0 + 𝜁𝜁1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 if 𝑇𝑇1 = 𝑇𝑇2 = 𝑎𝑎𝑎𝑎
𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 + 𝜉𝜉2𝑎𝑎𝑎𝑎,𝑣𝑣𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎.𝑁𝑁𝑅𝑅 if 𝑇𝑇1 = 𝑎𝑎𝑎𝑎,𝑇𝑇2 = 𝑣𝑣
𝜉𝜉0 + 𝜉𝜉1𝑎𝑎𝑎𝑎𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎 + 𝜉𝜉2𝑎𝑎𝑎𝑎.𝑚𝑚𝜇𝜇𝐿𝐿𝑎𝑎𝑎𝑎.𝑁𝑁𝑅𝑅 if 𝑇𝑇1 = 𝑎𝑎𝑎𝑎,𝑇𝑇2 = 𝑚𝑚
 
 and  
 𝑁𝑁𝑇𝑇1,𝑇𝑇2 =
⎝
⎜
⎜
⎛
𝑁𝑁𝑎𝑎𝛾𝛾𝑎𝑎 if 𝑇𝑇1 = 𝑇𝑇2 = 𝑎𝑎
𝑁𝑁𝑎𝑎(1 − 𝛾𝛾𝑎𝑎) × 12 if 𝑇𝑇1 = 𝑎𝑎,𝑇𝑇2 ∈ {𝑣𝑣,𝑚𝑚}
𝑁𝑁𝑎𝑎𝑎𝑎𝛾𝛾𝑎𝑎𝑎𝑎 if 𝑇𝑇1 = 𝑇𝑇2 = 𝑎𝑎𝑎𝑎
𝑁𝑁𝑎𝑎𝑎𝑎(1 − 𝛾𝛾𝑎𝑎𝑎𝑎) × 12 if 𝑇𝑇1 = 𝑎𝑎𝑎𝑎,𝑇𝑇2 ∈ {𝑣𝑣,𝑚𝑚}.
 
 If 𝑁𝑁𝑇𝑇1,𝑇𝑇2 contains a decimal part, then 𝑁𝑁𝑇𝑇1,𝑇𝑇2 = 𝑎𝑎𝑒𝑒𝑖𝑖𝑙𝑙𝑖𝑖𝑎𝑎𝑢𝑢(𝑁𝑁𝑇𝑇1,𝑇𝑇2). 
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Appendix Table 1: Parameter values for data generation corresponding to power curve and simulation studies. 
Parameter Power Curve 
Non-inferiority Equivalence 
    Control of Type-I error rate 
Distinct path Shared path Distinct path Shared path Distinct path Shared path 
𝜃𝜃 2 {3.0, 2.5} {3.0, 2.5} 2 2 2 2 
𝜎𝜎 2 3 3 4 4 4 4 
𝛼𝛼 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
𝛽𝛽 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
𝛾𝛾𝑎𝑎 0.3 0.30 0.50 
{0.50,0.45,0.4
0,0.35,0.30} 
{0.50,0.45,0.4
0,0.35,0.30} 
0.45 0.45 
𝛾𝛾𝑎𝑎𝑎𝑎 0.4 
{0.50,0.45,0.4
0,0.35,0.30} 
{0.50,0.45,0.4
0,0.35,0.30} 
{0.50,0.45,0.4
0,0.35,0.30} 
{0.50,0.45,0.4
0,0.35,0.30} 
0.45 0.45 
𝜇𝜇𝐿𝐿𝑎𝑎 2 2 2 2 2 2 2 
𝜎𝜎𝐿𝐿 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
𝜁𝜁0 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
𝜁𝜁1𝑎𝑎 0.5 0.8 0.8 0.5 0.5 0.5 0.5 
𝜁𝜁1𝑎𝑎𝑎𝑎 0.8 0.7 0.7 0.5 0.5 0.5 0.5 
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𝜉𝜉0 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
𝜉𝜉1𝑎𝑎 0.25 0.5 0.5 0.25 0.25 0.25 0.25 
𝜉𝜉2𝑎𝑎,𝑚𝑚 1.3 1.3 1.3 1 1 -1.01 -1.01 
𝜉𝜉2𝑎𝑎,𝑣𝑣 1.3 {0.01, -0.20} 0.3 1 1 1 1 
𝜉𝜉1𝑎𝑎𝑎𝑎 0.5 0.4 0.4 0.25 0.25 0.25 0.25 
𝜉𝜉2𝑎𝑎𝑎𝑎,𝑚𝑚 0.8 0.8 {-0.38, -0.53} 1 0.94 0.95 0.95 
𝜉𝜉2𝑎𝑎𝑎𝑎,𝑣𝑣 
{3.4,3.2,3.0,2
.8,2.6,2.4,2.2,
2.0,1.8,1.5,1.
3,1.0,0.8,0.6,
0.4,0.2,0,-
0.2,-0.4,-0.6,-
0.8,-2.0,-2.2,-
2.4,-2.6} 
0.8 0.8 0.95 0.95 1 -1 
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A.7 Simulated Data Analysis 
 
Here, we demonstrate how the developed methodologies can be applied in practice. In Appendix 
Table 2, we have four different data sets, indexed 1 through 4. The first data set is generated to 
answer the primary research question of whether the new adaptive intervention (investigational 
AI) is non-inferior to the standard adaptive intervention (control AI) with a non-inferiority margin 
θ = 2.5. Here, the comparison is for two distinct-path AIs and we have H0: New AI is inferior to 
standard AI, vs. H1: New AI is non-inferior to standard AI.  
Based on the prior data, we estimated the standardized effect size to be 0.23. Therefore, the 
estimated required sample size (N) from Table 2 is 234. Based on the simulated data set 1, the 
estimated mean outcomes for new and standard AIs are 0.94 and 2.27 respectively (using equation 
(2)). The variances of the two AIs can be estimated using equation (7). Using the test statistic for 
comparison of distinct-path AIs, the estimated p-value for the non-inferiority test is 0.0103. Based 
on the p-value, we reject the null hypothesis and conclude that the efficacy of the new AI is non-
inferior to the standard AI with respect to the non-inferiority margin θ = 2.5.  
To overcome the over-dependence on the p-value in the hypothesis testing, we have also reported 
the estimated upper bound of the Bayes Factor, defined as  1
− 𝑒𝑒 𝑝𝑝 log(𝑝𝑝), where 𝑝𝑝 denotes the p-
value (Benjamin and Berger, 2016; Bayarri et al., 2016).  
For the non-inferiority test based on the data set 1, the estimated upper bound of the Bayes Factor 
is 7.81. In other words, the data set 1 implies an odds in favor of the alternative hypothesis (non-
inferiority) relative to the null hypothesis (inferiority) of at most 7.81 to 1 (Benjamin and Berger, 
2016). 
The analysis results for other simulated data sets can be interpreted as above. Note that, for the 
equivalence test, we need to look at the p-values and upper bounds of the Bayes Factors for both 
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non-inferiority and non-superiority tests to make a decision about the rejection of the null 
hypothesis. The R-program for this data analysis is available in Open Science Framework 
(https://osf.io/hwae3/).  
 
Appendix Table 2: Data analysis report from four different simulated data sets 
 Data Set:1 Data Set:2 Data Set:3 Data Set:4 
Non-Inferiority (NI) 
or Equivalence (EQ) NI NI EQ EQ 
Comparison of AIs: 
Distinct (Di)/Shared (Sh) path  Di Sh Di Sh 
N 234 502 277 237 
Mean Outcome: Treatment AI 0.94 0.39 2.4 2.62 
Mean Outcome: Standard/Control 
AI 2.27 2.13 2.35 2.32 
p-value: Non-Inferiority Test 0.0103 0.01819 0.00243 0.00125  
Upper bound of the Bayes Factor: 
Non-Inferiority Test 7.81 5.05 25.15 44.03 
p-value: Non-superiority Test - - 0.00358 0.01262 
Upper bound of the Bayes Factor:  
Non-superiority Test - - 18.24 6.67 
Decision 
Reject the 
null 
hypothesis 
Reject the 
null 
hypothesis 
Reject the 
null 
hypothesis 
Reject the 
null 
hypothesis 
 
 
 
 
